PB 120 of 2010
National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2010
(No. 1)1
National Health Act 1953
I, FELICITY McNEILL, Acting First Assistant Secretary, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this Instrument under sections 84AF, 85, 85A, 88 and 101 of the National Health Act 1953.
Dated 15 December 2010
 
 
 
 
 
 
 
 
 
 
 
FELICITY McNEILL
Acting First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
 
1          Name of Instrument
            (1)        This Instrument is the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2010 (No. 1).
            (2)        This Instrument may also be cited as PB 120 of 2010.
2          Commencement
                        This Instrument commences on 1 January 2011.
3          Amendment of PB 108 of 2010
                        Schedule 1 amends PB 108 of 2010.
Schedule 1     Amendments
 
[1] Schedule 1, entry for Abacavir
omit from the column headed “Circumstances” (twice occurring):
C1820  C1821  C3309  C3310
insert:
C3586  C3587  C3588  C3589
[2] Schedule 1, entry for Abacavir with Lamivudine
omit from the column headed “Circumstances”:
C1822  C1823  C3311  C3312
insert:
C3590  C3591  C3592  C3593
[3] Schedule 1, entry for Abacavir with Lamivudine and Zidovudine
omit from the column headed “Circumstances”:
C1822  C1823  C3311  C3312
insert:
C3590  C3591  C3592  C3593
[4] Schedule 1, entry for Aciclovir
substitute:
Aciclovir
Tablet 200 mg
Oral
Acihexal
SZ
MP NP
C3632 C3633
P3632
50
0
 

 
 
 
Acyclo-V 200
AF
MP NP
C3632 C3633
P3632
50
0
 

 
 
 
GenRx Aciclovir
GX
MP NP
C3632 C3633
P3632
50
0
 

 
 
 
Lovir
GM
MP NP
C3632 C3633
P3632
50
0
 

 
 
 
 
Zovirax 200 mg
GK
MP NP
C3632 C3633
P3632
50
0
 

 
 
 
Aciclovir 200
CR
MP NP
C3633
P3633
90
5
 

 
 
 
Acihexal
SZ
MP NP
C3632 C3633
P3633
90
5
 

 
 
 
Acyclo-V 200
AF
MP NP
C3632 C3633
P3633
90
5
 

 
 
 
Chem mart Aciclovir
CH
MP NP
C3633
P3633
90
5
 

 
 
 
GenRx Aciclovir
GX
MP NP
C3632 C3633
P3633
90
5
 

 
 
 
Lovir
GM
MP NP
C3632 C3633
P3633
90
5
 

 
 
 
Ozvir
RA
MP NP
C3633
P3633
90
5
 

 
 
 
Terry White Chemists Aciclovir
TW
MP NP
C3633
P3633
90
5
 

 
 
 
Zovirax 200 mg
GK
MP NP
C3632 C3633
P3633
90
5
 

 
Tablet 800 mg
Oral
Aciclovir 800
CR
MP NP
C3622 C3631
P3622 P3631
35
0
 

 
 
 
Acihexal
SZ
MP NP
C3622 C3630 C3631
P3622 P3631
35
0
 

 
 
 
Acyclo-V 800
AF
MP NP
C3622 C3630 C3631
P3622 P3631
35
0
 

 
 
 
GenRx Aciclovir
GX
MP NP
C3622 C3631
P3622 P3631
35
0
 

 
 
 
Zovirax 800 mg
GK
MP NP
C3622 C3631
P3622 P3631
35
0
 

 
 
 
Acihexal
SZ
MP NP
C3622 C3630 C3631
P3630
120
5
 

 
 
 
Acyclo-V 800
AF
MP NP
C3622 C3630 C3631
P3630
120
5
 

 
Eye ointment 30 mg per g, 4.5 g
Application to the eye
Zovirax
GK
MP NP AO
C1715
 
1
0
 

[5] Schedule 1, after entry for Amlodipine with valsartan in the form Tablet 5 mg (as besylate)-160 mg
insert:
 
Tablet 5 mg (as besylate)-320 mg
Oral
Exforge 5/320
NV
MP NP
C3307
 
28
5
 
 
[6] Schedule 1, after entry for Amlodipine with valsartan in the form Tablet 10 mg (as besylate)-160 mg
insert:
 
Tablet 10 mg (as besylate)-320 mg
Oral
Exforge 10/320
NV
MP NP
C3307
 
28
5
 
[7] Schedule 1, entry for Aprepitant
omit from the column headed “Circumstances”:
C2071  C2330  C3446
insert:
C3619  C3620  C3621
[8] Schedule 1, entry for Atazanavir
omit from the column headed “Circumstances” (all instances):
C1832  C1833  C3315  C3316
insert:
C3586  C3587  C3588  C3589
[9] Schedule 1, entry for Azathioprine in the form Tablet 25 mg
omit from the column headed “Brand”:         Azahexal            and insert:            Azathioprine Sandoz
[10]             Schedule 1, entry for Benzydamine
substitute:
Benzydamine
Mouth and throat rinse containing benzydamine hydrochloride 22.5 mg per 15 mL, 500 mL
Oral application
Difflam
IA
MP NP
C1669 C3634 C3635
P3635
1
0
 

 
 
 
 
 
PDP
C1669
 
1
0
 

 
 
 
 
 
MP NP
C1669 C3634 C3635
P1669
1
1
 

 
 
 
 
 
MP NP
C1669 C3634 C3635
P3634
1
3
 

 
[11]             Schedule 1, entry for Bisacodyl
substitute:
Bisacodyl
Tablet 5 mg
Oral
Bisalax
AS
MP NP
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
P3643
200
0
 

 
 
 
Lax-Tab
AE
MP NP
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
P3643
200
0
 

 
 
 
Bisalax
AS
MP NP
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
P1025 P1122 P1221 P1254 P1263 P1268 P1400
200
2
 

 
 
 
Lax-Tab
AE
MP NP
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
P1025 P1122 P1221 P1254 P1263 P1268 P1400
200
2
 

 
 
 
Bisalax
AS
MP NP
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
P3642
200
3
 

 
 
 
Lax-Tab
AE
MP NP
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
P3642
200
3
 

 
 
Tablets 5 mg, 200
Oral
Bisalax
AS
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
PB

 
 
 
Lax-Tab
AE
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
PB

 
Suppositories 10 mg, 10
Rectal
Dulcolax
BY
MP NP
See Note 1
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P3643
See Note 2

3
See Note 2

0
See Note 2

 

 
 
 
Petrus Bisacodyl Suppositories
PP
MP NP
See Note 1
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P3643
See Note 2

3
See Note 2

0
See Note 2

 

 
 
 
Dulcolax
BY
MP NP
See Note 1
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P3642
See Note 2

3
See Note 2

3
See Note 2

 

 
 
 
Petrus Bisacodyl Suppositories
PP
MP NP
See Note 1
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P3642
See Note 2

3
See Note 2

3
See Note 2

 

 
 
 
Dulcolax
BY
MP NP
See Note 1
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P1025 P1122 P1221 P1254 P1263 P1268 P1400
See Note 2

3
See Note 2

5
See Note 2

 

 
 
 
Petrus Bisacodyl Suppositories
PP
MP NP
See Note 1
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P1025 P1122 P1221 P1254 P1263 P1268 P1400
See Note 2

3
See Note 2
5
See Note 2
 

 
 
Suppositories 10 mg, 12
Rectal
Petrus Bisacodyl Suppositories
PP
MP NP
See Note 1
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P3643
See Note 2

3
See Note 2

0
See Note 2

 

 
 
 
 
 
MP NP
See Note 1
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P3642
See Note 2

3
See Note 2

3
See Note 2

 

 
 
 
 
 
MP NP
See Note 1
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P1025 P1122 P1221 P1254 P1263 P1268 P1400
See Note 2

3
See Note 2

4
See Note 2

 

 
Enemas 10 mg in 5 mL, 25
Rectal
Bisalax
AS
MP NP
See Note 1
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P3643
See Note 2

1
See Note 2

0
See Note 2

 

 
 
 
 
 
MP NP
See Note 1
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P1025 P1122 P1221 P1254 P1263 P1268 P1400
See Note 2

1
See Note 2

2
See Note 2

 

 
 
 
Petrus Bisacodyl Suppositories
PP
NP
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P3642
See Note 2

3
See Note 2
5
See Note 2
 

 
[12]             Schedule 1, entry for Carvedilol in the form Tablet 3.125 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
APO-Carvedilol
TX
MP NP
C1735 C3234
 
30
0
 
[13]             Schedule 1, entry for Carmellose
omit:
 
Mouth spray containing carmellose sodium 10 mg per mL, 25 mL
Oral application
Aquae
HA
MP NP
C1899 C1900 C1901
P1901
1
0
 

 
 
 
 
 
MP NP
C1899 C1900 C1901
P1899 P1900
1
3
 

 
Mouth spray containing carmellose sodium 10 mg per mL, 100 mL
Oral application
Aquae
HA
MP NP
C1899 C1900 C1901
P1901
1
0
 

 
 
 
 
 
MP NP
C1899 C1900 C1901
P1899 P1900
1
3
 

insert in the columns in the order indicated:
 
Mouth spray containing carmellose sodium 10 mg per mL, 25 mL
Oral application
Aquae
HA
MP NP
C3636 C3637
P3637
1
0
 

 
 
 
 
 
MP NP
C3636 C3637
P3636
1
3
 

 
Mouth spray containing carmellose sodium 10 mg per mL, 100 mL
Oral application
Aquae
HA
MP NP
C3636 C3637
P3637
1
0
 

 
 
 
 
 
MP NP
C3636 C3637
P3636
1
3
 

 
[14]             Schedule 1, entry for Clonazepam
substitute:
Clonazepam
Tablet 500 micrograms
Oral
Paxam 0.5
AF
MP NP
C1574 C3657 C3658
P3658
100
0
 

 
 
 
Rivotril
RO
MP NP
C1574 C3657 C3658
P3658
100
0
 

 
 
 
Paxam 0.5
AF
MP NP
C1574 C3657 C3658
P3657
100
3
 

 
 
 
Rivotril
RO
MP NP
C1574 C3657 C3658
P3657
100
3
 

 
 
 
Paxam 0.5
AF
MP NP
C1574 C3657 C3658
P1574
200
2
 

 
 
 
Rivotril
RO
MP NP
C1574 C3657 C3658
P1574
200
2
 

 
Tablet 2 mg
Oral
Paxam 2
AF
MP NP
C1574 C3657 C3658
P3658
100
0
 

 
 
 
Rivotril
RO
MP NP
C1574 C3657 C3658
P3658
100
0
 

 
 
 
Paxam 2
AF
MP NP
C1574 C3657 C3658
P3657
100
3
 

 
 
 
Rivotril
RO
MP NP
C1574 C3657 C3658
P3657
100
3
 

 
 
 
Paxam 2
AF
MP NP
C1574 C3657 C3658
P3657
200
2
 

 
 
 
Rivotril
RO
MP NP
C1574 C3657 C3658
P1574
200
2
 

 
Oral liquid 2.5 mg per mL, 10 mL
Oral
Rivotril
RO
MP NP
C1574 C3657 C3658
P1574 P3658
2
0
 

 
 
 
 
RO
MP NP
C1574 C3657 C3658
P3657
2
3
 

 
Injection 1 mg in 2 mL (set containing solution 1 mg in 1 mL and 1 mL diluent)
Injection
Rivotril
RO
MP NP
C1093
 
5
0
 

 
[15]             Schedule 1, entry for Clopidogrel in the form Tablet 75 mg (as besilate)
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Clopidogrel Actavis
GQ
MP NP
C1719 C1720 C1721 C1722 C1723 C1724
 
28
5
 
[16]             Schedule 1, entry for Darunavir
omit from the column headed “Circumstances” (twice occurring):
C3279  C3335
insert:
C3594 C3595
[17]             Schedule 1, entry for Diazepam
substitute:
Diazepam
Tablet 2 mg
Oral
Antenex 2
AF
MP NP PDP
 
 
50
0
 

 
 
 
 
 
MP NP
 
P3656
50
0
 

 
 
 
Valium
RO
MP NP PDP
 
 
50
0
 

 
 
 
 
 
MP NP
 
P3656
50
0
 

 
 
 
Valpam 2
SI
MP NP PDP
 
 
50
0
 

 
 
 
 
 
MP NP
 
P3656
50
0
 

 
 
 
Antenex 2
AF
MP NP
 
P3655
50
3
 

 
 
 
Valium
RO
MP NP
 
P3655
50
3
 

 
 
 
Valpam 2
SI
MP NP
 
P3655
50
3
 

 
 
 
 
 
 
 
 
 
 
 

 
Tablet 5 mg
Oral
Antenex 5
AF
MP NP PDP
 
 
50
0
 

 
 
 
 
 
MP NP
 
P3656
50
0
 

 
 
 
Diazepam-GA
GM
MP NP PDP
 
 
50
0
 

 
 
 
 
 
MP NP
 
P3656
50
0
 

 
 
 
Ranzepam
RA
MP NP PDP
 
 
50
0
 

 
 
 
 
 
MP NP
 
P3656
50
0
 

 
 
 
Valium
RO
MP NP PDP
 
 
50
0
 

 
 
 
 
 
MP NP
 
P3656
50
0
 

 
 
 
Valpam 5
SI
MP NP PDP
 
 
50
0
 

 
 
 
 
 
MP NP
 
P3656
50
0
 

 
 
 
Antenex 5
AF
MP NP
 
P3655
50
3
 

 
 
 
Diazepam-GA
GM
MP NP
 
P3655
50
3
 

 
 
 
Ranzepam
RA
MP NP
 
P3655
50
3
 

 
 
 
Valium
RO
MP NP
 
P3655
50
3
 

 
 
 
Valpam 5
SI
MP NP
 
P3655
50
3
 

 
Injection 10 mg in 2 mL
Injection
Hospira Pty Limited
HH
MP NP PDP
 
 
5
0
 

[18]             Schedule 1, entry for Diclofenac
substitute:
Diclofenac
Tablet (enteric coated) containing diclofenac sodium 25 mg
Oral
APO-Diclofenac
TX
MP NP
C1036 C1054
C3645 C3646
P3646
100
0
 

 
 
 
 
 
PDP
C1036 C1054
 
100
0
 

 
 
 
Chem mart Diclofenac
CH
MP NP
C1036 C1054
C3645 C3646
P3646
100
0
 

 
 
 
 
 
PDP
C1036 C1054
 
100
0
 

 
 
 
Clonac 25
SI
MP NP
C1036 C1054
C3645 C3646
P3646
100
0
 

 
 
 
 
 
PDP
C1036 C1054
 
100
0
 

 
 
 
Diclofenac-GA
GM
MP NP
C1036 C1054
C3645 C3646
P3646
100
0
 

 
 
 
 
 
PDP
C1036 C1054
 
100
0
 

 
 
 
Diclofenac Sandoz
SZ
MP NP
C1036 C1054
C3645 C3646
P3646
100
0
 

 
 
 
 
 
PDP
C1036 C1054
 
100
0
 

 
 
 
Fenac 25
AF
MP NP
C1036 C1054
C3645 C3646
P3646
100
0
 

 
 
 
 
 
PDP
C1036 C1054
 
100
0
 

 
 
 
Terry White Chemists Diclofenac
TW
MP NP
C1036 C1054
C3645 C3646
P3646
100
0
 

 
 
 
 
 
PDP
C1036 C1054
 
100
0
 

 
 
 
Voltaren 25
NV
MP NP
C1036 C1054
C3645 C3646
P3646
100
0
 

 
 
 
 
 
PDP
C1036 C1054
 
100
0
 

 
 
 
APO-Diclofenac
TX
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
100
3
 

 
 
 
Chem mart Diclofenac
CH
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
100
3
 

 
 
 
Clonac 25
SI
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
100
3
 

 
 
 
Diclofenac-GA
GM
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
100
3
 

 
 
 
Diclofenac-GA
GM
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
100
3
 

 
 
 
Fenac 25
AF
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
100
3
 

 
 
 
Terry White Chemists Diclofenac
TW
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
100
3
 

 
 
 
Voltaren 25
NV
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
100
3
 

 
Tablet (enteric coated) containing diclofenac sodium 50 mg
Oral
APO-Diclofenac
TX
MP NP
C1036 C1054
C3645 C3646
P3646
50
0
 

 
 
 
 
 
PDP
C1036 C1054
P1036 P1054
50
0
 

 
 
 
Chem mart Diclofenac
CH
MP NP
C1036 C1054
C3645 C3646
P3646
50
0
 

 
 
 
 
 
PDP
C1036 C1054
P1036 P1054
50
0
 

 
 
 
Clonac 50
SI
MP NP
C1036 C1054
C3645 C3646
P3646
50
0
 

 
 
 
 
 
PDP
C1036 C1054
P1036 P1054
50
0
 

 
 
 
Diclofenac-GA
GM
MP NP
C1036 C1054
C3645 C3646
P3646
50
0
 

 
 
 
 
 
PDP
C1036 C1054
P1036 P1054
50
0
 

 
 
 
Diclofenac Sandoz
SZ
MP NP
C1036 C1054
C3645 C3646
P3646
50
0
 

 
 
 
 
 
PDP
C1036 C1054
P1036 P1054
50
0
 

 
 
 
Fenac
AF
MP NP
C1036 C1054
C3645 C3646
P3646
50
0
 

 
 
 
 
 
PDP
C1036 C1054
P1036 P1054
50
0
 

 
 
 
Terry White Chemists Diclofenac
TW
MP NP
C1036 C1054
C3645 C3646
P3646
50
0
 

 
 
 
 
 
PDP
C1036 C1054
P1036 P1054
50
0
 

 
 
 
Voltaren 50
NV
MP NP
C1036 C1054
C3645 C3646
P3646
50
0
 

 
 
 
 
 
PDP
C1036 C1054
P1036 P1054
50
0
 

 
 
 
APO-Diclofenac
TX
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
50
3
 

 
 
 
Chem mart Diclofenac
CH
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
50
3
 

 
 
 
Clonac 50
SI
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
50
3
 

 
 
 
Diclofenac-GA
GM
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
50
3
 

 
 
 
Diclofenac Sandoz
SZ
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
50
3
 

 
 
 
Fenac
AF
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
50
3
 

 
 
 
Terry White Chemists Diclofenac
TW
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
50
3
 

 
 
 
Voltaren 50
NV
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
50
3
 

 
Suppository containing diclofenac sodium 100 mg
Rectal
Voltaren 100
NV
MP NP
 
P3666
40
0
 

 
 
 
 
 
PDP
 
 
40
0
 

 
 
 
 
 
MP NP MW
 
 
40
3
 

 
 
 
 
 
MP NP
 
P3665
40
3
 

[19]             Schedule 1, entry for Didanosine
omit from the column headed “Circumstances” (all instances):
C1820  C1821  C3309  C3310
insert:
C3586  C3587  C3588  C3589
[20]             Schedule 1, after entry for Docetaxel in the form Injection set containing 1 single use vial concentrate for I.V. infusion 80 mg (anhydrous) in 2 mL with solvent
insert in the columns in the order indicated:
 
Solution concentrate for I.V. infusion 20 mg in 1 mL
Injection
Taxotere
SW
MP
See Note 1
C1194 C1742 C2416 C2439 C2732 C3051 C3292 C3428
P3051
1
0
 

 
 
 
 
 
MP
See Note 1
C1194 C1742 C2416 C2439 C2732 C3051 C3292 C3428
P1194 P1742 P2416 P2439 P2732 P3292 P3428
2
0
 

 
Solution concentrate for I.V. infusion 80 mg in 4 mL
Injection
Taxotere
SW
MP
See Note 1
C1194 C1742 C2416 C2439 C2732 C3051 C3292 C3428
 
1
0
 

[21]             Schedule 1, entry for Efavirenz
omit from the column headed “Circumstances” (all instances):
C1820  C1821  C3309  C3310
insert:
C3586  C3587  C3588  C3589
[22]             Schedule 1, entry for Emtricitabine
omit from the column headed “Circumstances”:
C1820  C1821  C3309  C3310
insert:
C3586  C3587  C3588  C3589
[23]             Schedule 1, entry for Enalapril in the form Tablet containing enalapril maleate 5 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Enalapril-GA
GM
MP NP
 
 
30
5
 
[24]             Schedule 1, entry for Enfuvirtide
omit from the column headed “Circumstances”:
C2007  C2008  C3350  C3351
insert:
C3596  C3597
[25]             Schedule 1, entry for Etravirine
omit from the column headed “Circumstances”:
C2956  C3354
substitute:
C3596  C3597
[26]             Schedule 1, entry for Famciclovir
substitute:
Famciclovir
Tablet 125 mg
Oral
APO-Famciclovir
TX
MP NP
C3624
 
40
1
 

 
 
 
Ezovir
AF
MP NP
C3624
 
40
1
 

 
 
 
Famvir
NV
MP NP
C3624
 
40
1
 

 
 
 
Favic 125
SI
MP NP
C3624
 
40
1
 

 
Tablet 250 mg
Oral
APO-Famciclovir
TX
MP NP
C3622 C3623 C3624
P3624
20
1
 

 
 
 
Ezovir
AF
MP NP
C3622 C3623 C3624
P3624
20
1
 

 
 
 
Famciclovir Sandoz
SZ
MP NP
C3622 C3623 C3624
P3624
20
1
 

 
 
 
Famvir
NV
MP NP
C3622 C3623 C3624
P3624
20
1
 

 
 
 
Favic 250
SI
MP NP
C3622 C3623 C3624
P3624
20
1
 

 
 
 
APO-Famciclovir
TX
MP NP
C3622 C3623 C3624
P3622
21
0
 

 
 
 
Ezovir
AF
MP NP
C3622 C3623 C3624
P3622
21
0
 

 
 
 
Famciclovir Sandoz
SZ
MP NP
C3622 C3623 C3624
P3622
21
0
 

 
 
 
Famvir
NV
MP NP
C3622 C3623 C3624
P3622
21
0
 

 
 
 
Favic 250
SI
MP NP
C3622 C3623 C3624
P3622
21
0
 

 
 
 
APO-Famciclovir
TX
MP NP
C3622 C3623 C3624
P3623
56
5
 

 
 
 
Ezovir
AF
MP NP
C3622 C3623 C3624
P3623
56
5
 

 
 
 
Famciclovir Sandoz
SZ
MP NP
C3622 C3623 C3624
P3623
56
5
 

 
 
 
Famvir
NV
MP NP
C3622 C3623 C3624
P3623
56
5
 

 
 
 
Favic 250
SI
MP NP
C3622 C3623 C3624
P3623
56
5
 

 
Tablet 500 mg
Oral
Famvir
NV
MP NP
C3625 C3626 C3627 C3628 C3629
P3625
30
0
 

 
 
 
Favic 500
SI
MP NP
C3625 C3626 C3627 C3628 C3629
P3625
30
0
 

 
 
 
Ezovir
AF
MP NP
C3625 C3626 C3627 C3628 C3629
P3626 P3627 P3628 P3629
56
5
 

 
 
 
Famvir
NV
MP NP
C3625 C3626 C3627 C3628 C3629
P3626 P3627 P3628 P3629
56
5
 

 
 
 
Favic 500
SI
MP NP
C3625 C3626 C3627 C3628 C3629
P3626 P3627 P3628 P3629
56
5
 

[27]             Schedule 1, omit entry for Fentanyl in the forms Lozenges 200 micrograms (as citrate), 3; Lozenges 400 micrograms (as citrate), 3; Lozenges 600 micrograms (as citrate), 3; Lozenges 800 micrograms (as citrate), 3; Lozenges 1200 micrograms (as citrate), 3; and Lozenges 1600 micrograms (as citrate), 3
insert in the columns in the order indicated:
Fentanyl
Lozenges 200 micrograms (as citrate), 3
Buccal
Actiq
OA
MP NP
C3663 C3664
P3663
3
0
 

 
 
 
 
 
MP NP
C3663 C3664
P3664
20
0
 

 
Lozenges 400 micrograms (as citrate), 3
Buccal
Actiq
OA
MP NP
C3663 C3664
P3663
3
0
 

 
 
 
 
 
MP NP
C3663 C3664
P3664
20
0
 

 
Lozenges 600 micrograms (as citrate), 3
Buccal
Actiq
OA
MP NP
C3663 C3664
P3663
3
0
 

 
 
 
 
 
MP NP
C3663 C3664
P3664
20
0
 

 
Lozenges 800 micrograms (as citrate), 3
Buccal
Actiq
OA
MP NP
C3663 C3664
P3663
3
0
 

 
 
 
 
 
MP NP
C3663 C3664
P3664
20
0
 

 
Lozenges 1200 micrograms (as citrate), 3
Buccal
Actiq
OA
MP NP
C3663 C3664
P3663
3
0
 

 
 
 
 
 
MP NP
C3663 C3664
P3664
20
0
 

 
Lozenges 1600 micrograms (as citrate), 3
Buccal
Actiq
OA
MP NP
C3663 C3664
P3663
3
0
 

 
 
 
 
 
MP NP
C3663 C3664
P3664
20
0
 

[28]             Schedule 1, entry for Fluconazole
omit from the column headed “Circumstances” (all instances):
C1199  C1854  C1855  C3240  C3295  C3296
insert:
C3613  C3614  C3615  C3616  C3617  C3618
[29]             Schedule 1, entry for Fosamprenavir in the form Tablet 700 mg (as calcium)
omit from the column headed “Responsible Person”: GK          and insert:            VI
[30]             Schedule 1, entry for Fosamprenavir
omit from the column headed “Circumstances” (twice occurring):
C1832  C1833  C3315  C3316
insert:
C3586  C3587  C3588  C3589
[31]             Schedule 1, entry for Frusemide in the form Injection 20 mg in 2 mL
omit from the column headed “Brand”:         Frusehexal        and insert:            Frusemide Sandoz
[32]             Schedule 1, entry for Gabapentin in the form Tablet 600 mg
omit:
 
 
 
Gabahexal 600mg
SZ
MP NP
C2664
 
100
5
 
[33]             Schedule 1, entry for Gemcitabine in the form Powder for I.V. infusion 200 mg (as hydrochloride)
(a)           insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Gemcitabine Kabi
PK
MP
See Note 1
C1193 C1194 C1740 C2069 C2141
 
4
2
 
(b)           insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Gemcitabine Sun
ZF
MP
See Note 1
C1193 C1194 C1740 C2069 C2141
 
4
2
 
[34]             Schedule 1, entry for Gemcitabine in the form Powder for I.V. infusion 1 g (as hydrochloride)
(a)            insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Gemcitabine Kabi
PK
MP
See Note 1
C1193 C1194 C1740 C2069 C2141
 
2
2
 
(b)            insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Gemcitabine Sun
ZF
MP
See Note 1
C1193 C1194 C1740 C2069 C2141
 
2
2
 
 
[35]             Schedule 1, entry for Gemcitabine in the form Powder for I.V. infusion 2 g (as hydrochloride)
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Gemcitabine Kabi
PK
MP
See Note 1
C1193 C1194 C1740 C2069 C2141
 
1
2
 
[36]             Schedule 1, entry for Gestrinone
omit from the column headed “Circumstances”:          C1377    and insert:            C3652
[37]             Schedule 1, entry for Glucose Indicator—Blood in the form Test strips, 50 (Bionime Rightest)
omit from the column headed “Responsible Person”: CQ          and insert:            QB
[38]             Schedule 1, entry for Glycerol
substitute:
Glycerol
Suppositories 700 mg, 12
Rectal
Petrus Pharmaceuticals Pty Ltd
PP
MP NP
See Note 1
C1025 C1122
C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P3643
See Note 2
3
See Note 2
0
See Note 2
 

 
 
 
 
 
MP NP
See Note 1
C1025 C1122
C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P3642
See Note 2
3
See Note 2
3
See Note 2
 

 
 
 
 
 
MP NP
See Note 1
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P1025 P1122 P1221 P1254 P1263 P1268 P1400
See Note 2
3
See Note 2
5
See Note 2
 

 
Suppositories 1.4 g, 12
Rectal
Petrus Pharmaceuticals Pty Ltd
PP
MP NP
See Note 1
C1025 C1122
C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P3643
See Note 2
3
See Note 2
0
See Note 2
 

 
 
 
 
 
MP NP
See Note 1
C1025 C1122
C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P3642
See Note 2
3
See Note 2
3
See Note 2
 

 
 
 
 
 
MP NP
See Note 1
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P1025 P1122 P1221 P1254 P1263 P1268 P1400
See Note 2
3
See Note 2
5
See Note 2
 

 
Suppositories 2.8 g, 12
Rectal
Petrus Pharmaceuticals Pty Ltd
PP
MP NP
See Note 1
C1025 C1122
C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P3643
See Note 2
3
See Note 2
0
See Note 2
 

 
 
 
 
 
MP NP
See Note 1
C1025 C1122
C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P3642
See Note 2
3
See Note 2
3
See Note 2
 

 
 
 
 
 
MP NP
See Note 1
C1025 C1122
C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P1025 P1122 P1221 P1254 P1263 P1268 P1400
See Note 2
3
See Note 2
5
See Note 2
 

 
[39]             Schedule 1, entry for Granisetron
substitute:
Granisetron
Tablet 2 mg (as hydrochloride)
Oral
Kytril
HH
MP NP
See Note 1
C3050 C3611
See Note 2
P3050
See Note 2
2
See Note 2
0
See Note 2
 

 
 
 
 
 
MP NP
See Note 1
C3050 C3611
See Note 2
P3611
See Note 2
5
See Note 2
1
See Note 2
 

 
Concentrated injection 3 mg (as hydrochloride) in 3 mL
Injection
Granisetron Kabi
PK
MP NP
See Note 1
C3050 C3611
See Note 2
 
1
See Note 2
0
See Note 2
 

 
 
 
Kytril
HH
MP NP
See Note 1
C3050 C3611
See Note 2
 
1
See Note 2
0
See Note 2
 

[40]             Schedule 1, entry for Hyoscine
substitute:
Hyoscine
Injection containing hyoscine butylbromide 20 mg in 1 mL
Injection
Buscopan
BY
MP NP
C3638 C3639
P3639
30
0
 

 
 
 
 
 
MP NP
C3638 C3639
P3638
30
3
 

[41]             Schedule 1, entry for Hypromellose
omit:
 
Oral gel 20 mg per g, 100 g
Oral application
Aquae Gel
HA
MP NP
C1899 C1900 C1901
P1901
1
0
 

 
 
 
 
 
MP NP
C1899 C1900 C1901
P1899 P1900
1
3
 

insert in the columns in the order indicated:
 
Oral gel 20 mg per g, 100 g
Oral application
Aquae Gel
HA
MP NP
C3636 C3637
P3637
1
0
 

 
 
 
 
 
MP NP
C3636 C3637
P3636
1
3
 

 
[42]             Schedule 1, entry for Ibuprofen
substitute:
Ibuprofen
Tablet 400 mg
Oral
Brufen
AB
MP NP MW PDP
 
 
30
0
 

 
 
 
 
 
MP NP
 
P3666
90
0
 

 
 
 
 
 
PDP
 
P1036 P1054
90
0
 

 
 
 
 
 
MP NP
 
P1036 P1054 P3665
90
3
 

[43]             Schedule 1, entry for Indinavir
omit from the column headed “Circumstances”:
C1820  C1821  C3309  C3310
insert:
C3586  C3587  C3588  C3589
[44]             Schedule 1, entry for Indomethacin
substitute:
Indomethacin
Capsule 25 mg
Oral
Arthrexin
AF
MP NP
C1036 C1054
C3645 C3646
P3646
100
0
 

 
 
 
 
 
PDP
C1036 C1054
 
100
0
 

 
 
 
Indocid
AS
MP NP
C1036 C1054
C3645 C3646
P3646
100
0
 

 
 
 
 
 
PDP
C1036 C1054
 
100
0
 

 
 
 
Arthrexin
AF
MP NP
C1036 C1054
C3645 C3646
P1036 P1054 P3645
100
3
 

 
 
 
Indocid
AS
MP NP
C1036 C1054
C3645 C3646
P1036 P1054 P3645
100
3
 

 
Suppository 100 mg
Rectal
Indocid
AS
MP NP
 
P3666
40
0
 

 
 
 
 
 
PDP
 
 
40
0
 

 
 
 
 
 
MP NP
 
 
40
3
 

 
 
 
 
 
MP NP
 
P3665
40
3
 

 
[45]             Schedule 1, entry for Itraconazole
omit all codes from the column headed “Circumstances” and substitute the following codes:
C3607  C3608  C3609  C3610  C3612  C3613  C3614
[46]             Schedule 1, omit entry for Ketoconazole in the form Tablet 200 mg
insert:
 
Tablet 200 mg
Oral
Nizoral
JC
MP NP
C3604 C3605 C3606
P3606
10
0
 

 
 
 
 
 
MP NP
C3604 C3605 C3606
P3604 P3605
30
5
 

[47]             Schedule 1, entry for Lactulose
substitute:
Lactulose
Solution BP 3.34 g per 5 mL, 500 mL
Oral
Actilax
AF
MP NP
C1150 C1613
C3642 C3643
P3643
3
0
 

 
 
 
Duphalac
SM
MP NP
C1150 C1613
C3642 C3643
P3643
3
0
 

 
 
 
Genlac
SI
MP NP
C1150 C1613
C3642 C3643
P3643
3
0
 

 
 
 
GenRx Lactulose
GX
MP NP
C1150 C1613
C3642 C3643
P3643
3
0
 

 
 
 
Lac-Dol
GM
MP NP
C1150 C1613
C3642 C3643
P3643
3
0
 

 
 
 
Lactocur
SZ
MP NP
C1150 C1613
C3642 C3643
P3643
3
0
 

 
 
 
Actilax
AF
MP NP
C1150 C1613
C3642 C3643
P3642
3
3
 

 
 
 
Duphalac
SM
MP NP
C1150 C1613
C3642 C3643
P3642
3
3
 

 
 
 
Genlac
SI
MP NP
C1150 C1613
C3642 C3643
P3642
3
3
 

 
 
 
GenRx Lactulose
GX
MP NP
C1150 C1613
C3642 C3643
P3642
3
3
 

 
 
 
Lac-Dol
GM
MP NP
C1150 C1613
C3642 C3643
P3642
3
3
 

 
 
 
Lactocur
SZ
MP NP
C1150 C1613
C3642 C3643
P3642
3
3
 

 
 
 
Actilax
AF
MP NP
C1150 C1613
C3642 C3643
P1150 P1613
1
5
 

 
 
 
Duphalac
SM
MP NP
C1150 C1613
C3642 C3643
P1150 P1613
1
5
 

 
 
 
Genlac
SI
MP NP
C1150 C1613
C3642 C3643
P1150 P1613
1
5
 

 
 
 
GenRx Lactulose
GX
MP NP
C1150 C1613
C3642 C3643
P1150 P1613
1
5
 

 
 
 
Lac-Dol
GM
MP NP
C1150 C1613
C3642 C3643
P1150 P1613
1
5
 

 
 
 
Lactocur
SZ
MP NP
C1150 C1613
C3642 C3643
P1150 P1613
1
5
 

[48]             Schedule 1, entry for Lamivudine in each of the forms Tablet 150 mg; Tablet 300 mg; and Oral solution 10 mg per mL, 240 mL
omit from the column headed “Circumstances”:
C1820  C1821  C3309  C3310
insert:
C3586  C3587  C3588  C3589
[49]             Schedule 1, entry for Lamivudine with Zidovudine
omit from the column headed “Circumstances”:
C1820  C1821  C3309  C3310
insert:
C3586  C3587  C3588  C3589
[50]             Schedule 1, entry for Lercanidipine in the forms Tablet containing lercanidipine hydrochloride 10 mg and Tablet containing lercanidipine hydrochloride 20 mg
(a)           insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Lercan
SI
MP NP
 
 
28
5
 
(b)           insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Lercanidipine Sandoz
SZ
MP NP
 
 
28
5
 
[51]             Schedule 1, entry for Lopinavir with Ritonavir
omit from the column headed “Circumstances” (all instances):
C1832  C1833  C3315  C3316
insert:
C3586  C3587  C3588  C3589
[52]             Schedule 1, entry for Macrogol 3350
substitute:
Macrogol 3350
Sachets containing powder for oral solution 13.125 g with electrolytes, 30
Oral
Movicol
NE
MP NP
See Note 1
C1263 C1613
C2693 C2823 C3642 C3643
See Note 2
P3643
See Note 2
2
See Note 2
0
See Note 2
 

 
 
 
 
 
MP NP
See Note 1
C1263 C1613
C2693 C2823 C3642 C3643
See Note 2
P3642
See Note 2
2
See Note 2
3
See Note 2
 

 
 
 
 
 
MP NP
See Note 1
C1263 C1613
C2693 C2823 C3642 C3643
See Note 2
P1263 P1613
P2693 P2823
See Note 2
1
See Note 2
5
See Note 2
 

 
Powder for oral solution 510 g
Oral
MediHealth ClearLax
ON
MP NP
C1263 C1613
C2693 C2823 C3642 C3643
P3643

2
0
 

 
 
 
OsmoLax
KY
MP NP
C1263 C1613
C2693 C2823 C3642 C3643
P3643

2
0
 

 
 
 
MediHealth ClearLax
ON
MP NP
C1263 C1613
C2693 C2823 C3642 C3643
P3642

2
3
 

 
 
 
OsmoLax
KY
MP NP
C1263 C1613
C2693 C2823 C3642 C3643
P3642

2
3
 

 
 
 
MediHealth ClearLax
ON
MP NP
C1263 C1613
C2693 C2823 C3642 C3643
P1263 P1613 P2693 P2823
1
5
 

 
 
 
OsmoLax
KY
MP NP
C1263 C1613
C2693 C2823 C3642 C3643
P1263 P1613 P2693 P2823
1
5
 

[53]             Schedule 1, entry for Maraviroc
(a)           omit from the column headed “Responsible Person” (twice occurring):                VI            and insert:            PF
(b)           omit from the column headed “Circumstances” (twice occurring):
C3286  C3406
insert:
C3598  C3599
[54]             Schedule 1, after entry for Mesalazine in the form Suppository 1 g
insert in the columns in the order indicated:
 
Suppository 1g (moulded)
Rectal
Salofalk
OA
MP NP
C1978
 
30
1
 
[55]             Schedule 1, entry for Metformin in the form Tablet (extended release) containing metformin hydrochloride 1 g
omit from the column headed “Responsible Person”: AF          and insert:            AL
[56]             Schedule 1, entry for Methadone
omit:
 
Oral liquid containing methadone hydrochloride 25 mg per 5 mL, 200 mL
Oral
Biodone Forte
MW
MP NP
See Note 1
See Note 2
See Note 2
See Note 2
See Note 2
PB

 
 
 
Sigma Pharmaceuticals (Australia) Pty Ltd
SI
MP NP
See note 1
C2348 C2349 C2350
See Note 2
P2350
See Note 2
1
See Note 2
0
See Note 2
 

 
 
 
 
 
MP NP
C2348 C2349 C2350
See Note 2
P2348 P2349
See Note 2
1
See Note 2
2
See Note 2
 

insert in the columns in the order indicated:
 
Oral liquid containing methadone hydrochloride 25 mg per 5 mL, 200 mL
Oral
Biodone Forte
MW
MP NP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
PB

 
 
 
Sigma Pharmaceuticals (Australia) Pty Ltd
SI
MP NP
See Note 1
C3659 C3660
See Note 2
P3660
See Note 2
1
See Note 2
0
See Note 2
 

 
 
 
 
 
MP NP
See Note 1
C3659 C3660
See Note 2
P3659
See Note 2
1
See Note 2
2
See Note 2
 

[57]             Schedule 1, entry for Methylnaltrexone
substitute:
Methylnaltrexone
Solution for injection containing methylnaltrexone bromide 12 mg in 0.6 mL
Injection
Relistor
WX
MP NP
C3235 C3238
P3235
3
0
 

 
 
 
 
 
MP NP
C3235 C3238
P3238
7
0
 

[58]             Schedule 1, entry for Morphine
(a)     omit:
 
Tablet containing morphine sulfate 10 mg
Oral
Sevredol
MF
MP NP
C1789 C2351 C2352 C2353
P1789 P2353
20
0
 

 
 
 
 
 
MP NP
C1789 C2351 C2352 C2353
P2351 P2352
20
2
 

 
Tablet containing morphine sulfate 20 mg
Oral
Sevredol
MF
MP NP
C1789 C2351 C2352 C2353
P1789 P2353
20
0
 

 
 
 
 
 
MP NP
C1789 C2351 C2352 C2353
P2351 P2352
20
2
 

insert in the columns in the order indicated:
 
Tablet containing morphine sulfate 10 mg
Oral
Sevredol
MF
MP NP
C1789 C3661 C3662
P1789 P3662
20
0
 

 
 
 
 
 
MP NP
C1789 C3661 C3662
P1789 P3661
20
2
 

 
Tablet containing morphine sulfate 20 mg
Oral
Sevredol
MF
MP NP
C1789 C3661 C3662
P1789 P3662
20
0
 

 
 
 
 
 
MP NP
C1789 C3661 C3662
P1789 P3661
20
2
 

(b)     omit:
 
Tablet containing morphine sulfate 200 mg (controlled release)
Oral
MS Contin
MF
MP NP
C1499 C2348 C2349 C2350
P1499 P2350
20
0
 

 
 
 
 
 
MP NP
C1499 C2348 C2349 C2350
P2348 P2349
20
2
 

insert in the columns in the order indicated:
 
Tablet containing morphine sulfate 200 mg (controlled release)
Oral
MS Contin
MF
MP NP
C1499 C3659 C3600
P1499 P3660
20
0
 

 
 
 
 
 
MP NP
C1499 C3659 C3600
P3659
20
2
 

[59]             Schedule 1, entry for Naproxen
substitute:
Naproxen
Tablet 250 mg
Oral
Inza 250
AF
MP NP
C1036 C1054
C3645 C3646
P3646
100
0
 

 
 
 
 
 
PDP
C1036 C1054
 
100
0
 

 
 
 
Naprosyn
RO
MP NP
C1036 C1054
C3645 C3646
P3646
100
0
 

 
 
 
 
 
PDP
C1036 C1054
 
100
0
 

 
 
 
Inza 250
AF
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
100
3
 

 
 
 
Naprosyn
RO
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
100
3
 

 
Tablet containing naproxen sodium 550 mg
Oral
Anaprox 550
RO
MP NP
C1036 C1054
C3645 C3646
P3646
50
0
 

 
 
 
 
 
PDP
C1036 C1054
 
50
0
 

 
 
 
Crysanal
MD
MP NP
C1036 C1054
C3645 C3646
P3646
50
0
 

 
 
 
 
 
PDP
C1036 C1054
 
50
0
 

 
 
 
Anaprox 550
RO
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
50
3
 

 
 
 
Crysanal
MD
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
50
3
 

 
Tablet 500 mg
Oral
Inza 500
AF
MP NP
C1036 C1054
C3645 C3646
P3646
50
0
 

 
 
 
 
 
PDP
C1036 C1054
 
50
0
 

 
 
 
Naprosyn
RO
MP NP
C1036 C1054
C3645 C3646
P3646
50
0
 

 
 
 
 
 
PDP
C1036 C1054
P1036 P1054
50
0
 

 
 
 
Inza 500
AF
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
50
3
 

 
 
 
Naprosyn
RO
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
50
3
 

 
Tablet 750 mg (sustained release)
Oral
Naprosyn SR750
RO
MP NP
C1036 C1054
C3645 C3646
P3646
28
0
 

 
 
 
 
 
PDP
C1036 C1054
 
28
0
 

 
 
 
Proxen SR 750
MD
MP NP
C1036 C1054
C3645 C3646
P3646
28
0
 

 
 
 
 
 
PDP
C1036 C1054
 
28
0
 

 
 
 
Naprosyn SR750
RO
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
28
3
 

 
 
 
Proxen SR 750
MD
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
28
3
 

 
Tablet 1 g (sustained release)
Oral
Naprosyn SR1000
RO
MP NP
C1036 C1054
C3645 C3646
P3646
28
0
 

 
 
 
 
 
PDP
C1036 C1054
 
28
0
 

 
 
 
Proxen SR 1000
MD
MP NP
C1036 C1054
C3645 C3646
P3646
28
0
 

 
 
 
 
 
PDP
C1036 C1054
 
28
0
 

 
 
 
Naprosyn SR1000
RO
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
28
3
 

 
 
 
Proxen SR 1000
MD
MP NP
C1036 C1054
C3645 C3646
P1036 P1054
P3645
28
3
 

 
Oral suspension 125 mg per 5 mL, 474 mL
Oral
Naprosyn
RO
MP NP
C2270 C2271
C3647 C3648
P3648
1
0
 

 
 
 
 
 
MP NP
C2270 C2271
C3647 C3648
P2270 P2271
P3647
1
3
 

[60]             Schedule 1, entry for Nevirapine
omit from the column headed “Circumstances” (twice occurring):
C1820  C1821  C3309  C3310
insert:
C3586  C3587  C3588  C3589
[61]             Schedule 1, entry for Nitrazepam
substitute:
Nitrazepam
Tablet 5 mg
Oral
Alodorm
AF
MP NP PDP
 
 
25
0
 

 
 
 
Mogadon
VT
MP NP PDP
 
 
25
0
 

 
 
 
Alodorm
AF
MP NP
 
P3654
50
0
 

 
 
 
Mogadon
VT
MP NP
 
P3654
50
0
 

 
 
 
Alodorm
AF
MP NP
 
P3653
50
3
 

 
 
 
Mogadon
VT
MP NP
 
P3653
50
3
 

 
 
 
Alodorm
AF
MP NP
 
P1123 P1126 P1216 P1235
50
5
 

 
 
 
Mogadon
VT
MP NP
 
P1123 P1126 P1216 P1235
50
5
 

[62]             Schedule 1, omit entry for Omeprazole in the form Capsule 20 mg
insert in the columns in the order indicated:
 
Capsule 20 mg
Oral
Omepro-GA
GM
MP NP
C1177 C1337 C1476 C1533
P1177
30
1
 

 
 
 
Pemzo
SI
MP NP
C1177 C1337 C1476 C1533
P1177
30
1
 

 
 
 
Pharmacor Omeprazole 20
CR
MP NP
C1177 C1337 C1476 C1533
P1177
30
1
 

 
 
 
Probitor
SZ
MP NP
C1177 C1337 C1476 C1533
P1177
30
1
 

 
 
 
Omepro-GA
GM
MP NP
C1177 C1337 C1476 C1533
P1337 P1476 P1533
30
5
 

 
 
 
Pemzo
SI
MP NP
C1177 C1337 C1476 C1533
P1337 P1476 P1533
30
5
 

 
 
 
Pharmacor Omeprazole 20
CR
MP NP
C1177 C1337 C1476 C1533
P1337 P1476 P1533
30
5
 

 
 
 
Probitor
SZ
MP NP
C1177 C1337 C1476 C1533
P1337 P1476 P1533
30
5
 

[63]             Schedule 1, entry for Omeprazole and Clarithromycin and Amoxycillin in the form Pack containing 14 capsules omeprazole 20 mg, 14 tablets clarithromycin 500 mg and 28 capsules amoxycillin 500 mg (as trihydrate)
omit:
 
 
 
Klacid Hp 7
AB
MP NP
C1096
 
30
5
 
[64]             Schedule 1, entry for Ondansetron
substitute:
Ondansetron
Tablet 4 mg (as hydrochloride dihydrate)
Oral
APO-Ondansetron
TX
MP NP
See Note 1
C3050 C3611
See Note 2
P3050
See Note 2
4
See Note 2
0
See Note 2
 

 
 
 
Ondaz
SZ
MP NP
See Note 1
C3050 C3611
See Note 2
P3050
See Note 2
4
See Note 2
0
See Note 2
 

 
 
 
Onsetron 4
ZP
MP NP
See Note 1
C3050 C3611
See Note 2
P3050
See Note 2
4
See Note 2
0
See Note 2
 

 
 
 
Zofran
GK
MP NP
See Note 1
C3050 C3611
See Note 2
P3050
See Note 2
4
See Note 2
0
See Note 2
 

 
 
 
APO-Ondansetron
TX
MP NP
C3050 C3611
P3611
10
1
 

 
 
 
Ondaz
SZ
MP NP
C3050 C3611
P3611
10
1
 

 
 
 
Onsetron 4
ZP
MP NP
C3050 C3611
P3611
10
1
 

 
 
 
Zofran
GK
MP NP
C3050 C3611
P3611
10
1
 

 
Tablet 8 mg (as hydrochloride dihydrate)
Oral
APO-Ondansetron
TX
MP NP
See Note 1
C3050 C3611
See Note 2
P3050
See Note 2
4
See Note 2
0
See Note 2
 

 
 
 
Ondaz
SZ
MP NP
See Note 1
C3050 C3611
See Note 2
P3050
See Note 2
4
See Note 2
0
See Note 2
 

 
 
 
Onsetron 8
ZP
MP NP
See Note 1
C3050 C3611
See Note 2
P3050
See Note 2
4
See Note 2
0
See Note 2
 

 
 
 
Zofran
GK
MP NP
See Note 1
C3050 C3611
See Note 2
P3050
See Note 2
4
See Note 2
0
See Note 2
 

 
 
 
APO-Ondansetron
TX
MP NP
C3050 C3611
P3611
10
1
 

 
 
 
Ondaz
SZ
MP NP
C3050 C3611
P3611
10
1
 

 
 
 
Onsetron 8
ZP
MP NP
C3050 C3611
P3611
10
1
 

 
 
 
Zofran
GK
MP NP
C3050 C3611
P3611
10
1
 

 
Wafer 4 mg
Oral
Ondaz Zydis
SZ
MP NP
See Note 1
C3050 C3611
See Note 2
P3050
See Note 2
4
See Note 2
0
See Note 2
 

 
 
 
Zofran Zydis
GK
MP NP
See Note 1
C3050 C3611
See Note 2
P3050
See Note 2
4
See Note 2
0
See Note 2
 

 
 
 
Ondaz Zydis
SZ
MP NP
C3050 C3611
P3611
10
1
 

 
 
 
Zofran Zydis
GK
MP NP
C3050 C3611
P3611
10
1
 

 
Wafer 8 mg
Oral
Ondaz Zydis
SZ
MP NP
See Note 1
C3050 C3611
See Note 2
P3050
See Note 2
4
See Note 2
0
See Note 2
 

 
 
 
Zofran Zydis
GK
MP NP
See Note 1
C3050 C3611
See Note 2
P3050
See Note 2
4
See Note 2
0
See Note 2
 

 
 
 
Ondaz Zydis
SZ
MP NP
C3050 C3611
P3611
10
1
 

 
 
 
Zofran Zydis
GK
MP NP
C3050 C3611
P3611
10
1
 

 
Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL
Oral
Zofran syrup 50 mL
GK
MP NP
See Note 1
C3050 C3611
See Note 2
P3050
See Note 2
1
See Note 2
0
See Note 2
 

 
 
 
 
 
MP NP
C3050 C3611
P3611
1
1
 

 
I.V. injection 4 mg (as hydrochloride dihydrate) in 2 mL
Injection
Ondansetron-Claris
AE
MP NP
See Note 1
C3050 C3611
See Note 2
See Note 2
1
See Note 2
0
See Note 2
 

 
 
 
Ondaz
SZ
MP NP
See Note 1
C3050 C3611
See Note 2
See Note 2
1
See Note 2
0
See Note 2
 

 
 
 
Onsetron
ZP
MP NP
See Note 1
C3050 C3611
See Note 2
See Note 2
1
See Note 2
0
See Note 2
 

 
 
 
Pfizer Australia Pty Ltd
PF
MP NP
See Note 1
C3050 C3611
See Note 2
See Note 2
1
See Note 2
0
See Note 2
 

 
 
 
Zofran
GK
MP NP
See Note 1
C3050 C3611
See Note 2
See Note 2
1
See Note 2
0
See Note 2
 

 
I.V. injection 8 mg (as hydrochloride dihydrate) in 4 mL
Injection
Ondansetron-Claris
AE
MP NP
See Note 1
C3050 C3611
See Note 2
See Note 2
1
See Note 2
0
See Note 2
 

 
 
 
Ondaz
SZ
MP NP
See Note 1
C3050 C3611
See Note 2
See Note 2
1
See Note 2
0
See Note 2
 

 
 
 
Onsetron
ZP
MP NP
See Note 1
C3050 C3611
See Note 2
See Note 2
1
See Note 2
0
See Note 2
 

 
 
 
Pfizer Australia Pty Ltd
PF
MP NP
See Note 1
C3050 C3611
See Note 2
See Note 2
1
See Note 2
0
See Note 2
 

 
 
 
Zofran
GK
MP NP
See Note 1
C3050 C3611
See Note 2
See Note 2
1
See Note 2
0
See Note 2
 

[65]             Schedule 1, entry for Oxaliplatin in the form Solution concentrate for I.V. infusion 50 mg in 10 mL
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”::
 
 
 
Oxaliplatin Kabi
PK
MP
See Note 1
C2717 C3449 C3450
 
1
2
 
[66]             Schedule 1, entry for Oxaliplatin in the forms Powder for I.V. infusion 50 mg and Powder for I.V. infusion 100 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Xalox
WQ
MP
See Note 1
C2717 C3449 C3450
 
1
2
 
[67]             Schedule 1, entry for Oxazepam
substitute:
Oxazepam
Tablet 15 mg
Oral
Alepam 15
AF
MP NP PDP
 
 
25
0
 

 
 
 
Serepax
SI
MP NP PDP
 
 
25
0
 

 
 
 
Alepam 15
AF
MP NP
 
P3656
50
0
 

 
 
 
Serepax
SI
MP NP
 
P3656
50
0
 

 
 
 
Alepam 15
AF
MP NP
 
P3655
50
3
 

 
 
 
Serepax
SI
MP NP
 
P3655
50
3
 

 
 
 
Alepam 15
AF
MP NP
 
P1123 P1126 P1216
50
5
 

 
 
 
Serepax
SI
MP NP
 
P1123 P1126 P1216
50
5
 

 
Tablet 30 mg
Oral
Alepam 30
AF
MP NP PDP
 
 
25
0
 

 
 
 
APO-Oxazepam
TX
MP NP PDP
 
 
25
0
 

 
 
 
Murelax
FM
MP NP PDP
 
 
25
0
 

 
 
 
Serepax
SI
MP NP PDP
 
 
25
0
 

 
 
 
Alepam 30
AF
MP NP
 
P3656
50
0
 

 
 
 
APO-Oxazepam
TX
MP NP
 
P3656
50
0
 

 
 
 
Murelax
FM
MP NP
 
P3656
50
0
 

 
 
 
Serepax
SI
MP NP
 
P3656
50
0
 

 
 
 
Alepam 30
AF
MP NP
 
P3655
50
3
 

 
 
 
APO-Oxazepam
TX
MP NP
 
P3655
50
3
 

 
 
 
Murelax
FM
MP NP
 
P3655
50
3
 

 
 
 
Serepax
SI
MP NP
 
P3655
50
3
 

 
 
 
Alepam 30
AF
MP NP
 
P1123 P1126 P1216
50
5
 

 
 
 
APO-Oxazepam
TX
MP NP
 
P1123 P1126 P1216
50
5
 

 
 
 
Murelax
FM
MP NP
 
P1123 P1126 P1216
50
5
 

 
 
 
Serepax
SI
MP NP
 
P1123 P1126 P1216
50
5
 

[68]             Schedule 1, entry for Paclitaxel in the form Solution concentrate for I.V. infusion 30 mg in 5 mL
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Paclitaxel Kabi
PK
MP
See Note 1
C1194 C1293 C1742 C2417 C2439 C3428
 
5
0
 
[69]             Schedule 1, entry for Paclitaxel in the form Solution concentrate for I.V. infusion 100 mg in 16.7 mL
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Paclitaxel Kabi
PK
MP
See Note 1
C1194 C1293 C1742 C2417 C2439 C3428
 
2
0
 
[70]             Schedule 1, entry for Paclitaxel in the form Solution concentrate for I.V. infusion 300 mg in 50 mL
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Paclitaxel Kabi
PK
MP
See Note 1
C1194 C1293 C1742 C2417 C2439 C3428
 
1
0
 
 
[71]             Schedule 1, entry for Paracetamol
(a)            omit:
 
Tablet 665 mg (modified release)
Oral
Panadol Osteo
GC
MP NP
C1890 C1891 C1892 C2094
P1892
192
0
 

 
 
 
 
 
MP NP
C1890 C1891 C1892 C2094
P1890 P1891
192
3
 

 
 
 
 
 
MP NP
C1890 C1891 C1892 C2094
P2094
192
5
 

insert in the columns in the order indicated:
 
Tablet 665 mg (modified release)
Oral
Panadol Osteo
GC
MP NP
C2094 C3649 C3650
P3650
192
0
 

 
 
 
 
 
MP NP
C2094 C3649 C3650
P3649
192
3
 

 
 
 
 
 
MP NP
C2094 C3649 C3650
P2094
192
5
 

(b)            omit:
 
Suppositories 500 mg, 24
Rectal
Panadol
GC
MP NP
C1890 C1891 C1892
P1892
1
0
 

 
 
 
 
 
MP NP
C1890 C1891 C1892
P1890 P1891
1
3
 

insert in the columns in the order indicated:
 
Suppositories 500 mg, 24
Rectal
Panadol
GC
MP NP
C3649 C3650
P3650
4
0
 

 
 
 
 
 
MP NP
C3649 C3650
P3649
4
3
 

[72]             Schedule 1, entry for Promethazine
omit:
 
Tablet containing promethazine hydrochloride 10 mg
Oral
Phenergan
SW
MP NP
C1896 C1897 C1898
P1898
50
0
 

 
 
 
 
 
MP NP
C1896 C1897 C1898
P1896 P1897
50
3
 

 
Tablet containing promethazine hydrochloride 25 mg
Oral
Phenergan
SW
MP NP
C1896 C1897 C1898
P1898
50
0
 

 
 
 
 
 
MP NP
C1896 C1897 C1898
P1896 P1897
50
3
 

 
Oral liquid containing promethazine hydrochloride 5 mg per 5 mL, 100 mL
Oral
Phenergan
SW
MP NP
C1896 C1897 C1898
P1898
1
0
 

 
 
 
 
 
MP NP
C1896 C1897 C1898
P1896 P1897
1
3
 

insert in the columns in the order indicated:
 
Tablet containing promethazine hydrochloride 10 mg
Oral
Phenergan
SW
MP NP
C3640 C3641
P3641
50
0
 

 
 
 
 
 
MP NP
C3640 C3641
P3640
50
3
 

 
Tablet containing promethazine hydrochloride 25 mg
Oral
Phenergan
SW
MP NP
C3640 C3641
P3641
50
0
 

 
 
 
 
 
MP NP
C3640 C3641
P3640
50
3
 

 
Oral liquid containing promethazine hydrochloride 5 mg per 5 mL, 100 mL
Oral
Phenergan
SW
MP NP
C3640 C3641
P3641
1
0
 

 
 
 
 
 
MP NP
C3640 C3641
P3640
1
3
 

[73]             Schedule 1, after entry for Quetiapine in the form Tablet (modified release) 50 mg (as fumarate)
insert in the columns in the order indicated:
 
Tablet (modified release) 150 mg (as fumarate)
Oral
Seroquel XR
AP
MP NP
C1589 C2044 C2765
 
60
5
 
[74]             Schedule 1, entry for Raltegravir
omit from the column headed “Circumstances”:
C3505  C3506  C3507  C3508
insert:
C3586  C3587  C3588  C3589
[75]             Schedule 1, entry for Ramipril in the forms Capsule 2.5 mg and Capsule 10 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Ramipril-GA
GM
MP NP
 
 
30
5
 
[76]             Schedule 1, entry for Ranitidine in the form Tablet 300 mg (as hydrochloride)
omit:
 
 
 
Ranihexal
HX
MP NP
 
 
30
5
 
[77]             Schedule 1, entry for Ritonavir
omit from the column headed “Circumstances” (twice occurring):
C1820  C1821  C3309  C3310
insert:
C3586  C3587  C3588  C3589
[78]             Schedule 1, entry for Saquinavir
omit from the column headed “Circumstances”:
C1820  C1821  C3309  C3310
insert:
C3586  C3587  C3588  C3589
[79]             Schedule 1, entry for Somatropin in the form Solution for injection 10 mg (30 i.u.) in 1.5 mL cartridge (with preservative)
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Omnitrope
SZ
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
D
[80]             Schedule 1, entry for Sorbitol with Sodium Citrate and Sodium Lauryl Sulfoacetate
substitute:
Sorbitol with Sodium Citrate and Sodium Lauryl Sulfoacetate
Enemas 3.125 g-450 mg-45 mg in 5 mL, 12
Rectal
Micolette
AE
MP NP
See Note 1
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P3643
See Note 2
2
See Note 2
0
See Note 2
 

 
 
 
Microlax
JT
MP NP
See Note 1
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P3643
See Note 2
2
See Note 2
0
See Note 2
 

 
 
 
Micolette
AE
MP NP
See Note 1
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P1025 P1122 P1221 P1254 P1263 P1268 P1400
See Note 2
2
See Note 2
2
See Note 2
 

 
 
 
Microlax
JT
MP NP
See Note 1
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P1025 P1122 P1221 P1254 P1263 P1268 P1400
See Note 2
2
See Note 2
2
See Note 2
 

 
 
 
Micolette
AE
MP NP
See Note 1
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P3642
See Note 2
2
See Note 2
3
See Note 2
 

 
 
 
Microlax
JT
MP NP
See Note 1
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P3642
See Note 2
2
See Note 2
3
See Note 2
 

[81]             Schedule 1, entry for Stavudine
omit from the column headed “Circumstances” (all instances):
C1820  C1821  C3309  C3310
insert:
C3586  C3587  C3588  C3589
[82]             Schedule 1, entry for Sterculia with Frangula Bark
substitute:
Sterculia with Frangula Bark
Granules 620 mg-80 mg per g, 500 g
Oral
Normacol Plus
NE
MP NP
See Note 1
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P3643
See Note 2
1
See Note 2
0
See Note 2
 

 
 
 
 
 
MP NP
See Note 1
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P1025 P1122 P1221 P1254 P1263 P1268 P1400
See Note 2
1
See Note 2
1
See Note 2
 

 
 
 
 
 
MP NP
See Note 1
C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2
P3642
See Note 2
1
See Note 2
3
See Note 2
 

[83]             Schedule 1, entry for Sulindac
substitute:
Sulindac
Tablet 100 mg
Oral
Aclin
AF
MP NP
C1036 C1054 C3645 C3646
P3646
100
0
 

 
 
 
 
 
PDP
C1036 C1054
P1036 P1054
100
0
 

 
 
 
 
 
MP NP
C1036 C1054
C3645 C3646

P1036 P1054
P3645
100
3
 

 
Tablet 200 mg
Oral
Aclin 200
AF
MP NP
C1036 C1054 C3645 C3646
P3646
50
0
 

 
 
 
 
 
PDP
C1036 C1054
P1036 P1054
50
0
 

 
 
 
 
 
MP NP
C1036 C1054
C3645 C3646

P1036 P1054
P3645
50
3
 

[84]             Schedule 1, entry for Sumatriptan in the form Tablet 50 mg (as succinate)
(a)            insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
APO-Sumatriptan
TX
MP NP
C3233
 
4
5
 
(b)            insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Chem mart Sumatriptan
CH
MP NP
C3233
 
4
5
 
(c)             insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Terry White Chemists Sumatriptan
TW
MP NP
C3233
 
4
5
 
[85]             Schedule 1, entry for Temazepam
substitute:
Temazepam
Tablet 10 mg
Oral
APO-Temazepam
TX
PDP MP NP
 
 
25
0
 

 
 
 
Normison
SI
PDP MP NP
 
 
25
0
 

 
 
 
Temaze
AF
PDP MP NP
 
 
25
0
 

 
 
 
Temtabs
FM
PDP MP NP
 
 
25
0
 

 
 
 
APO-Temazepam
TX
MP NP
 
P3654
50
0
 

 
 
 
Normison
SI
MP NP
 
P3654
50
0
 

 
 
 
Temaze
AF
MP NP
 
P3654
50
0
 

 
 
 
Temtabs
FM
MP NP
 
P3654
50
0
 

 
 
 
APO-Temazepam
TX
MP NP
 
P3653
50
3
 

 
 
 
Normison
SI
MP NP
 
P3653
50
3
 

 
 
 
Temaze
AF
MP NP
 
P3653
50
3
 

 
 
 
Temtabs
FM
MP NP
 
P3653
50
3
 

 
 
 
APO-Temazepam
TX
MP NP
 
P1123 P1126 P1216
50
5
 

 
 
 
Normison
SI
MP NP
 
P1123 P1126 P1216
50
5
 

 
 
 
Temaze
AF
MP NP
 
P1123 P1126 P1216
50
5
 

 
 
 
Temtabs
FM
MP NP
 
P1123 P1126 P1216
50
5
 

[86]             Schedule 1, entry for Tenofovir
omit from the column headed “Circumstances”:
C1820  C1821  C2931  C3203  C3309  C3310  C3313  C3417
insert:
C2931  C3203  C3313  C3417  C3586  C3587  C3588  C3589
[87]             Schedule 1, entry for Tenofovir with Emtricitabine
omit from the column headed “Circumstances”:
C1820  C1821  C3309  C3310
insert:
C3586  C3587  C3588  C3589
[88]             Schedule 1, entry for Tenofovir with emtricitabine and efavirenz
omit from the column headed “Circumstances”:
C1820  C1821  C3309  C3310
insert:
C3586  C3587  C3588  C3589
[89]             Schedule 1, entry for Testosterone
omit:
 
Injection containing testosterone esters (20 mg testosterone propionate, 40 mg testosterone phenylpropionate, 40 mg testosterone isocaproate) in 1 mL
Injection
Sustanon 100
SH
MP
C1021 C1022 C1226
 
3
3
 
[90]             Schedule 1, entry for Tipranavir in the form Capsule 250 mg
omit from the column headed “Circumstances”:
C2700  C3418
insert:
C3600  C3601
[91]             Schedule 1, entry for Tipranavir in the form Oral liquid 100 mg per mL, 95 mL
omit from the column headed “Circumstances”:
C3500  C3501
insert:
C3602  C3603
[92]             Schedule 1, entry for Tramadol in the form Tablet (sustained release) containing tramadol hydrochloride 150 mg
omit from the column headed “Brand”:         Tramahexal      and insert:            Tramadol Sandoz SR
[93]             Schedule 1, entry for Valaciclovir
substitute:
Valaciclovir
Tablet 500 mg (as hydrochloride)
Oral
Valtrex
GK
MP NP
C3622 C3631 C3632 C3633
P3632
20
0
 

 
 
 
 
 
MP NP
C3622 C3631 C3632 C3633
P3633
30
5
 

 
 
 
 
 
MP NP
C3622 C3631 C3632 C3633
P3622 P3631
42
0
 

 
 
 
 
 
MP
See Note 1
C1494 C3419
 
500
2
C

[94]             Schedule 1, entry for Zidovudine
omit from the column headed “Circumstances” (all instances):
C1820  C1821  C3309  C3310
insert:
C3586  C3587  C3588  C3589
[95]             Schedule 3, omit Responsible person code CQ and relevant details
[96]             Schedule 3, after details relevant to Responsible person code PZ
insert:
QB
Bionime Australia Pty Ltd
 84 142 133 677
[97]             Schedule 3, after details relevant to Responsible person code YT
insert:
ZF
Sun Pharmaceutical Industries Pty Ltd
 64 130119603
[98]             Schedule 4, entry for Abacavir
substitute:
Abacavir
C3586
 
Where the patient is receiving treatment at/from a private hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures

 
C3587
 
Where the patient is receiving treatment at/from a private hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures

 
C3588
 
Where the patient is receiving treatment at/from a public hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3588

 
C3589
 
Where the patient is receiving treatment at/from a public hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3589

[99]             Schedule 4, entry for Abacavir with Lamivudine
substitute:
Abacavir with Lamivudine
C3590
 
Where the patient is receiving treatment at/from a private hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient over 12 years of age, weighing 40 kg or more, with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures

 
C3591
 
Where the patient is receiving treatment at/from a private hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient over 12 years of age, weighing 40 kg or more, has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures

 
C3592
 
Where the patient is receiving treatment at/from a public hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient over 12 years of age, weighing 40 kg or more, with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3592

 
C3593
 
Where the patient is receiving treatment at/from a public hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient over 12 years of age, weighing 40 kg or more, has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3593

[100]          Schedule 4, entry for Abacavir with Lamivudine and Zidovudine
substitute:
Abacavir with Lamivudine and Zidovudine
C3590
 
Where the patient is receiving treatment at/from a private hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient over 12 years of age, weighing 40 kg or more, with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures

 
C3591
 
Where the patient is receiving treatment at/from a private hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient over 12 years of age, weighing 40 kg or more, has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures

 
C3592
 
Where the patient is receiving treatment at/from a public hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient over 12 years of age, weighing 40 kg or more, with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3592

 
C3593
 
Where the patient is receiving treatment at/from a public hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient over 12 years of age, weighing 40 kg or more, has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3593

 
[101]          Schedule 4, entry for Aciclovir
substitute:
Aciclovir
C1715
 
Herpes simplex keratitis.
 

 
C3622
P3622
Treatment of patients with herpes zoster within 72 hours of the onset of the rash
Compliance with Authority Required procedures - Streamlined Authority Code 3622

 
C3630
P3630
Patients with advanced human immunodeficiency virus disease (CD4 cell counts of less than 150 million per L)
Compliance with Authority Required procedures - Streamlined Authority Code 3630

 
C3631
P3631
Herpes zoster ophthalmicus
Compliance with Authority Required procedures - Streamlined Authority Code 3631

 
C3632
P3632
Moderate to severe initial genital herpes
Compliance with Authority Required procedures - Streamlined Authority Code 3632

 
C3633
P3633
Episodic treatment or suppressive therapy of moderate to severe recurrent genital herpes, where the diagnosis is confirmed microbiologically (by viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction) but where commencement of treatment need not await confirmation of diagnosis
Compliance with Authority Required procedures - Streamlined Authority Code 3633

[102]          Schedule 4, entry for Aprepitant
substitute:
Aprepitant
C3619
 
Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy, in combination with a 5-hydroxytryptamine type 3 receptor antagonist and dexamethasone, where any 1 of the following chemotherapy agents are to be administered:
(a) altretamine;
(b) carmustine;
(c) cisplatin, when a single dose constitutes a cycle of chemotherapy;
(d) cyclophosphamide, at a dose of 1500 mg per square metre per day or greater;
(e) dacarbazine;
(f) procarbazine, when a single dose constitutes a cycle of chemotherapy;
(g) streptozocin; and
where treatment with aprepitant is limited to an initial dose of 125 mg and 2 subsequent doses of 80 mg per cycle of cytotoxic chemotherapy
Compliance with Authority Required procedures - Streamlined Authority Code 3619


 
C3620
 
Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat breast cancer, in combination with a 5-hydroxytryptamine type 3 receptor antagonist and dexamethasone, where cyclophosphamide and an anthracycline are to be co-administered, and where treatment with aprepitant is limited to an initial dose of 125 mg and 2 subsequent doses of 80 mg per cycle of cytotoxic chemotherapy
Compliance with Authority Required procedures - Streamlined Authority Code 3620

 
C3621
 
Management of nausea and vomiting associated with moderately emetogenic cytotoxic chemotherapy being used to treat malignancy, in combination with a 5-hydroxytryptamine type 3 receptor (5HT3) antagonist and dexamethasone on day 1, where the patient has had a prior episode of chemotherapy induced nausea or vomiting where any 1 of the following intravenous chemotherapy agents is to be administered:
(a) arsenic trioxide;
(b) azacitidine;
(c) carboplatin;
(d) cyclophosphamide, at a dose of less than 1500 mg per square metre per day;
(e) cytarabine, at a dose of greater than 1 g per square metre per day;
(f) dactinomycin;
(g) daunorubicin;
(h) doxorubicin;
(i) epirubicin;
(j) fotemustine;
(k) idarubicin;
(l) ifosfamide;
(m) irinotecan;
(n) melphalan;
(o) methotrexate, at a dose of 250 mg to 1 g per square metre;
(p) oxaliplatin;
(q) raltitrexed; and
where treatment with aprepitant is limited to an initial dose of 125 mg and 2 subsequent doses of 80 mg per cycle of cytotoxic chemotherapy, and where concomitant use of a 5HT3 antagonist should not occur with aprepitant on days 2 and 3 of any chemotherapy cycle
Compliance with Authority Required procedures - Streamlined Authority Code 3621


 
[103]          Schedule 4, entry for Atazanavir
substitute:
Atazanavir
C3586
 
Where the patient is receiving treatment at/from a private hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures

 
C3587
 
Where the patient is receiving treatment at/from a private hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures

 
C3588
 
Where the patient is receiving treatment at/from a public hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3588

 
C3589
 
Where the patient is receiving treatment at/from a public hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3589

[104]          Schedule 4, entry for Benzydamine
substitute:
Benzydamine
C1669
P1669
Radiation induced mucositis
 

 
C3634
P3634
Initial supply, for up to 4 months, for a palliative care patient where a painful mouth is a problem
Compliance with Authority Required procedures - Streamlined Authority Code 3634

 
 
 
 
 

 
C3635
P3635
Continuing supply for a palliative care patient where a painful mouth is a problem
Compliance with Authority Required procedures - Streamlined Authority Code 3635

[105]          Schedule 4, entry for Bisacodyl
substitute:
Bisacodyl
C1025
P1025
Anorectal congenital abnormalities
 

 
C1122
P1122
For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult
 

 
C1221
P1221
Megacolon
 

 
C1254
P1254
Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function
 

 
C1263
P1263
Patients receiving palliative care
 

 
C1268
P1268
Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities
 

 
C1400
P1400
Terminal malignant neoplasia
 

 
C3642
P3642
Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem
Compliance with Authority Required procedures - Streamlined Authority Code 3642

 
C3643
P3643
Continuing supply for a palliative care patient where constipation is a problem
Compliance with Authority Required procedures - Streamlined Authority Code 3643

 
[106]          Schedule 4, entry for Carmellose
substitute:
Carmellose
C1359
 
Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops
Compliance with Authority Required procedures - Streamlined Authority Code 1359

 
C1362
P1362
Severe dry eye syndrome, including Sjogren's syndrome.
 

 
C2802
 
Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops
Compliance with Authority Required procedures

 
C3036
P3036
For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements
 

 
C3636
P3636
Initial supply, for up to 4 months, for a palliative care patient where dry mouth is a symptom
Compliance with Authority Required procedures - Streamlined Authority Code 3636

 
C3637
P3637
Continuing supply for a palliative care patient where dry mouth is a symptom
Compliance with Authority Required procedures - Streamlined Authority Code 3637

[107]          Schedule 4, entry for Clonazepam
substitute:
Clonazepam
C1093
 
Epilepsy.
 

 
C1574
P1574
Neurologically proven epilepsy
Compliance with Authority Required procedures

 
C3657
P3657
Initial supply, for up to 4 months, for a palliative care patient for the prevention of epilepsy
Compliance with Authority Required procedures

 
C3658
P3658
Continuing supply for a palliative care patient for the prevention of epilepsy
Compliance with Authority Required procedures

[108]          Schedule 4, entry for Darunavir
substitute:
Darunavir
C3594
 
Where the patient is receiving treatment at/from a private hospital
Treatment of human immunodeficiency virus (HIV) infection, in addition to optimised background therapy in combination with other antiretroviral agents, and co-administered with 100 mg ritonavir twice daily in an antiretroviral experienced patient who, after at least one antiretroviral regimen, has experienced virological failure or clinical failure or genotypic resistance
Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity
Compliance with Written or Telephone Authority Required procedures

 
C3595
 
Where the patient is receiving treatment at/from a public hospital
Treatment of human immunodeficiency virus (HIV) infection, in addition to optimised background therapy in combination with other antiretroviral agents, and co-administered with 100 mg ritonavir twice daily in an antiretroviral experienced patient who, after at least one antiretroviral regimen, has experienced virological failure or clinical failure or genotypic resistance
Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3595


[109]          Schedule 4, entry for Diazepam
substitute:
Diazepam
 
P3655
Initial supply, for up to 4 months, for a palliative care patient where anxiety is a problem (Authority Required)
 

 
 
P3656
Continuing supply for a palliative care patient where anxiety is a problem (Authority Required)
 

[110]          Schedule 4, entry for Diclofenac
substitute:
Diclofenac
C1036
P1036
Bone pain due to malignant disease
 

 
C1054
P1054
Chronic arthropathies (including osteoarthritis) with an inflammatory component
 
 
 
 

 
C3645
P3645
Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem
Compliance with Authority Required procedures - Streamlined Authority Code 3645

 
C3646
P3646
Continuing supply for a palliative care patient where severe pain is a problem
Compliance with Authority Required procedures - Streamlined Authority Code 3646

 
 
P3665
Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem (Authority Required)
 

 
 
P3666
Continuing supply for a palliative care patient where severe pain is a problem. (Authority Required)
 

[111]          Schedule 4, entry for Didanosine
substitute:
Didanosine
C3586
 
Where the patient is receiving treatment at/from a private hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures

 
C3587
 
Where the patient is receiving treatment at/from a private hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures

 
C3588
 
Where the patient is receiving treatment at/from a public hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3588
 
 
 
 

 
C3589
 
Where the patient is receiving treatment at/from a public hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3589

[112]          Schedule 4, entry for Dipyridamole
substitute:
Dipyridamole
C1725
 
Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients receiving therapy with low-dose aspirin
 

 
C1726
 
Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding
 

 
C1727
 
Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or non-steroidal anti-inflammatory drugs
 

[113]          Schedule 4, entry for Efavirenz
substitute:
Efavirenz
C3586
 
Where the patient is receiving treatment at/from a private hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures

 
C3587
 
Where the patient is receiving treatment at/from a private hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures

 
C3588
 
Where the patient is receiving treatment at/from a public hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3588
 

 
C3589
 
Where the patient is receiving treatment at/from a public hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3589

[114]          Schedule 4, entry for Emtricitabine
substitute:
Emtricitabine
C3586
 
Where the patient is receiving treatment at/from a private hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures

 
C3587
 
Where the patient is receiving treatment at/from a private hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures

 
C3588
 
Where the patient is receiving treatment at/from a public hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Wrtten or Telephone Authority Required procedures - Streamlined Authority Code 3588

 
C3589
 
Where the patient is receiving treatment at/from a public hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Wrtten or Telephone Authority Required procedures - Streamlined Authority Code 3589

 
[115]          Schedule 4, entry for Enfuvirtide
substitute:
Enfuvirtide
C3596
 
Where the patient is receiving treatment at/from a private hospital
Treatment of human immunodeficiency virus (HIV) infection, in addition to optimised background therapy in combination with other antiretroviral agents in an antiretroviral experienced patient who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance.
Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity
Compliance with Written or Telephone Authority Required procedures

 
C3597
 
Where the patient is receiving treatment at/from a public hospital
Treatment of human immunodeficiency virus (HIV) infection, in addition to optimised background therapy in combination with other antiretroviral agents in an antiretroviral experienced patient who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance.
Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3597


[116]          Schedule 4, entry for Etravirine
substitute:
Etravirine
C3596
 
Where the patient is receiving treatment at/from a private hospital
Treatment of human immunodeficiency virus (HIV) infection, in addition to optimised background therapy in combination with other antiretroviral agents in an antiretroviral experienced patient who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance.
Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity
Compliance with Written or Telephone Authority Required procedures

 
C3597
 
Where the patient is receiving treatment at/from a public hospital
Treatment of human immunodeficiency virus (HIV) infection, in addition to optimised background therapy in combination with other antiretroviral agents in an antiretroviral experienced patient who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance
Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3597


[117]          Schedule 4, entry for Famciclovir
substitute:
Famciclovir
C3622
P3622
Treatment of patients with herpes zoster within 72 hours of the onset of the rash
Compliance with Authority Required procedures - Streamlined Authority Code 3622

 
C3623
P3623
Suppressive therapy of moderate to severe recurrent genital herpes, where the diagnosis is confirmed microbiologically (by viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction) but where commencement of treatment need not await confirmation of diagnosis
Compliance with Authority Required procedures - Streamlined Authority Code 3623

 
C3624
P3624
Episodic treatment of moderate to severe recurrent genital herpes, where the diagnosis is confirmed microbiologically (by viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction) but where commencement of treatment need not await confirmation of diagnosis
Compliance with Authority Required procedures - Streamlined Authority Code 3624

 
C3625
P3625
Treatment of immunocompromised patients with herpes zoster within 72 hours of the onset of the rash
Compliance with Authority Required procedures - Streamlined Authority Code 3625

 
C3626
P3626
Episodic treatment or suppressive therapy of moderate to severe recurrent genital herpes in immunocompromised patients, where the diagnosis is confirmed microbiologically (by viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction) but where commencement of treatment need not await confirmation of diagnosis
Compliance with Authority Required procedures - Streamlined Authority Code 3626

 
C3627
P3627
Episodic treatment of moderate to severe recurrent oral or labial herpes in a patient with human immunodeficiency virus infection and a CD4 cell count of less than 500 million per L, where the diagnosis is confirmed microbiologically (by viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction) but where commencement of treatment need not await confirmation of diagnosis
Compliance with Authority Required procedures - Streamlined Authority Code 3627
 

 
C3628
P3628
Suppressive therapy of moderate to severe recurrent oral or labial herpes in a patient with human immunodeficiency virus infection and a CD4 cell count of less than 150 million per L, where the diagnosis is confirmed microbiologically (by viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction) but where commencement of treatment need not await confirmation of diagnosis
Compliance with Authority Required procedures - Streamlined Authority Code 3628

 
C3629
P3629
Suppressive therapy of moderate to severe recurrent oral or labial herpes in a patient with human immunodeficiency virus infection and other opportunistic infections or Acquired Immunodeficiency Syndrome defining tumours, where the diagnosis is confirmed microbiologically (by viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction) but where commencement of treatment need not await confirmation of diagnosis
Compliance with Authority Required procedures - Streamlined Authority Code 3629

[118]          Schedule 4, entry for Fentanyl
substitute:
Fentanyl
C1062
 
Chronic severe disabling pain not responding to non-narcotic analgesics
 

 
C3663
P3663
Initial supply for dose titration for breakthrough pain in a palliative care patient with cancer who is receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects
Compliance with Authority Required procedures

 
C3664
P3664
Continuing supply for breakthrough pain in a palliative care patient with cancer who is receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects
Compliance with Authority Required procedures

[119]          Schedule 4, entry for Fluconazole
substitute:
Fluconazole
C3613
 
Treatment of oropharyngeal candidiasis in immunosuppressed patients
Compliance with Authority Required procedures - Streamlined Authority Code 3613

 
C3614
 
Treatment of oesophageal candidiasis in immunosuppressed patients
Compliance with Authority Required procedures - Streamlined Authority Code 3614
 
 
 

 
C3615
 
Treatment of cryptococcal meningitis
Compliance with Authority Required procedures - Streamlined Authority Code 3615

 
C3616
 
Maintenance therapy in patients with cryptococcal meningitis and immunosuppression
Compliance with Authority Required procedures - Streamlined Authority Code 3616

 
C3617
 
Prophylaxis of oropharyngeal candidiasis in immunosuppressed patients
Compliance with Authority Required procedures - Streamlined Authority Code 3617

 
C3618
 
Treatment of serious and life-threatening candida infections
Compliance with Authority Required procedures - Streamlined Authority Code 3618

[120]          Schedule 4, entry for Fosamprenavir
substitute:
Fosamprenavir
C3586
 
Where the patient is receiving treatment at/from a private hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures

 
C3587
 
Where the patient is receiving treatment at/from a private hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Wriitten or Telephone Authority Required procedures

 
C3588
 
Where the patient is receiving treatment at/from a public hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3588

 
C3589
 
Where the patient is receiving treatment at/from a public hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3589

[121]          Schedule 4, entry for Gestrinone
substitute:
Gestrinone
C3652
 
Short term treatment (up to 6 months) of visually proven endometriosis (only 1 course of not more than 6 months’ therapy may be prescribed)
Compliance with Authority Required procedures - Streamlined Authority Code 3652
[122]          Schedule 4, entry for Glycerol
substitute:
Glycerol
C1025
P1025
Anorectal congenital abnormalities
 

 
C1122
P1122
For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult
 

 
C1221
P1221
Megacolon
 

 
C1254
P1254
Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function
 

 
C1263
P1263
Patients receiving palliative care
 

 
C1268
P1268
Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities
 

 
C1400
P1400
Terminal malignant neoplasia
 

 
C3642
P3642
Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem
Compliance with Authority Required procedures - Streamlined Authority Code 3642

 
C3643
P3643
Continuing supply for a palliative care patient where constipation is a problem
Compliance with Authority Required procedures - Streamlined Authority Code 3643

[123]          Schedule 4, entry for Granisetron
substitute:
Granisetron
C3050
P3050
Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration
 

 
C3611
P3611
Management of nausea and vomiting associated with radiotherapy being used to treat malignancy
Compliance with Authority Required procedures - Streamlined Authority Code 3611

[124]          Schedule 4, entry for Hyoscine
substitute:
Hyoscine
C3638
P3638
Initial supply, for up to 4 months, for a palliative care patient where colicky pain is a symptom
Compliance with Authority Required procedures - Streamlined Authority Code 3638

 
C3639
P3639
Continuing supply for a palliative care patient where colicky pain is a symptom
Compliance with Authority Required procedures - Streamlined Authority Code 3639

[125]          Schedule 4, entry for Hypromellose
substitute:
Hypromellose
C1362
P1362
Severe dry eye syndrome, including Sjogren's syndrome
 

 
C3036
P3036
For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements
 

 
C3636
P3636
Initial supply, for up to 4 months, for a palliative care patient where dry mouth is a symptom
Compliance with Authority Required procedures - Streamlined Authority Code 3636

 
C3637
P3637
Continuing supply for a palliative care patient where dry mouth is a symptom
Compliance with Authority Required procedures - Streamlined Authority Code 3637

[126]          Schedule 4, entry for Ibuprofen
substitute:
Ibuprofen
 
P1036
Bone pain due to malignant disease
 

 
 
P1054
Chronic arthropathies (including osteoarthritis) with an inflammatory component
 

 
 
P3665
Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem (Authority Required)
 

 
 
P3666
Continuing supply for a palliative care patient where severe pain is a problem. (Authority Required)
 

[127]          Schedule 4, entry for Indinavir
substitute:
Indinavir
C3586
 
Where the patient is receiving treatment at/from a private hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures

 
C3587
 
Where the patient is receiving treatment at/from a private hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures
 
 
 

 
C3588
 
Where the patient is receiving treatment at/from a public hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3588

 
C3589
 
Where the patient is receiving treatment at/from a public hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3589

[128]          Schedule 4, entry for Indomethacin
substitute:
Indomethacin
C1036
P1036
Bone pain due to malignant disease
 

 
C1054
P1054
Chronic arthropathies (including osteoarthritis) with an inflammatory component
 

 
C3645
P3645
Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem
Compliance with Authority Required procedures - Streamlined Authority Code 3645


 
C3646
P3646
Continuing supply for a palliative care patient where severe pain is a problem
Compliance with Authority Required procedures - Streamlined Authority Code 3646

 
 
P3665
Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem (Authority Required)
 

 
 
P3666
Continuing supply for a palliative care patient where severe pain is a problem. (Authority Required)
 

 
[129]          Schedule 4, entry for Itraconazole
substitute:
Itraconazole
C3607
 
Systemic aspergillosis
Compliance with Authority Required procedures - Streamlined Authority Code 3607

 
C3608
 
Systemic sporotrichosis
Compliance with Authority Required procedures - Streamlined Authority Code 3608

 
C3609
 
Systemic histoplasmosis
Compliance with Authority Required procedures - Streamlined Authority Code 3609

 
C3610
 
Treatment and maintenance therapy in patients with Acquired Immunodeficiency Syndrome who have disseminated pulmonary histoplasmosis infection
Compliance with Authority Required procedures - Streamlined Authority Code 3610


 
C3612
 
Treatment and maintenance therapy in patients with Acquired Immunodeficiency Syndrome who have chronic pulmonary histoplasmosis infection
Compliance with Authority Required procedures - Streamlined Authority Code 3612

 
C3613
 
Treatment of oropharyngeal candidiasis in immunosuppressed patients
Compliance with Authority Required procedures - Streamlined Authority Code 3613
 

 
C3614
 
Treatment of oesophageal candidiasis in immunosuppressed patients
Compliance with Authority Required procedures - Streamlined Authority Code 3614

[130]          Schedule 4, entry for Ketoconazole
substitute:
Ketoconazole
C2354
 
Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person
Compliance with Authority Required procedures - Streamlined Authority Code 2354

 
C3604
P3604
Oral candidiasis in severely immunocompromised persons where topical therapy has failed
Compliance with Authority Required procedures - Streamlined Authority Code 3604

 
C3605
P3605
Systemic or deep mycoses where other forms of therapy have failed
Compliance with Authority Required procedures - Streamlined Authority Code 3605

 
C3606
P3606
Symptomatic genital candidiasis recurring after treatment of at least 2 episodes with topical therapy
Compliance with Authority Required procedures - Streamlined Authority Code 3606

[131]          Schedule 4, entry for Lactulose
substitute:
Lactulose
C1150
P1150
Hepatic coma or precoma (chronic porto-systemic encephalopathy)
 

 
C1613
P1613
Constipation in patients with malignant neoplasia
 

 
C3642
P3642
Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem
Compliance with Authority Required procedures - Streamlined Authority Code 3642

 
C3643
P3643
Continuing supply for a palliative care patient where constipation is a problem
Compliance with Authority Required procedures - Streamlined Authority Code 3643

[132]          Schedule 4, entry for Lamivudine
substitute:
Lamivudine
C2932
 
Where the patient is receiving treatment at/from a private hospital
Patients with chronic hepatitis B who satisfy all of the following criteria:
(1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);
(2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or
(b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;
(3) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception
Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy
Compliance with Written or Telephone Authority Required procedures

 
C3386
 
Where the patient is receiving treatment at/from a public hospital
Patients with chronic hepatitis B who satisfy all of the following criteria:
(1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);
(2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or
(b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;
(3) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception
Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3386


 
C3586
 
Where the patient is receiving treatment at/from a private hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures

 
C3587
 
Where the patient is receiving treatment at/from a private hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures

 
C3588
 
Where the patient is receiving treatment at/from a public hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3588

 
C3589
 
Where the patient is receiving treatment at/from a public hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3589

[133]          Schedule 4, entry for Lamivudine with Zidovudine
substitute:
Lamivudine with Zidovudine
C3586
 
Where the patient is receiving treatment at/from a private hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures

 
C3587
 
Where the patient is receiving treatment at/from a private hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures

 
C3588
 
Where the patient is receiving treatment at/from a public hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3588

 
C3589
 
Where the patient is receiving treatment at/from a public hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3589

[134]          Schedule 4, entry for Lopinavir with Ritonavir
substitute:
Lopinavir with Ritonavir
C3586
 
Where the patient is receiving treatment at/from a private hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures

 
C3587
 
Where the patient is receiving treatment at/from a private hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures

 
C3588
 
Where the patient is receiving treatment at/from a public hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3588

 
C3589
 
Where the patient is receiving treatment at/from a public hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3589

 
[135]          Schedule 4, entry for Macrogol 3350
substitute:
Macrogol 3350
C1263
P1263
Patients receiving palliative care
 

 
C1613
P1613
Constipation in patients with malignant neoplasia
 

 
C2693
P2693
Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function not responding to other oral therapies
 

 
C2823
P2823
Chronic constipation or faecal impaction not adequately controlled with first line interventions such as bulk-forming agents
 

 
C3642
P3642
Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem
Compliance with Authority Required procedures - Streamlined Authority Code 3642

 
C3643
P3643
Continuing supply for a palliative care patient where constipation is a problem
Compliance with Authority Required procedures - Streamlined Authority Code 3643

[136]          Schedule 4, entry for Maraviroc
substitute:
Maraviroc
C3598
 
Where the patient is receiving treatment at/from a private hospital
Treatment, in addition to optimised background therapy in combination with other antiretroviral agents, of an antiretroviral experienced patient infected with only CCR5-tropic human immunodeficiency virus type 1 (HIV-1), who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance. A tropism assay to determine CCR5 only strain status is required prior to initiation. Individuals with CXCR4 tropism demonstrated at any time point are not eligible
Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity
Compliance with Written or Telephone Authority Required procedures

 
C3599
 
Where the patient is receiving treatment at/from a public hospital
Treatment, in addition to optimised background therapy in combination with other antiretroviral agents, of an antiretroviral experienced patient infected with only CCR5-tropic human immunodeficiency virus type 1 (HIV-1), who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance. A tropism assay to determine CCR5 only strain status is required prior to initiation. Individuals with CXCR4 tropism demonstrated at any time point are not eligible
Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3599


[137]          Schedule 4, entry for Mesalazine
omit from the column headed “Circumstances and Purposes” (all instances):
Crohn’s disease
and substitute:
Crohn disease
[138]          Schedule 4, entry for Methadone
substitute:
Methadone
C1358
 
Severe disabling pain not responding to non-narcotic analgesics
 

 
C3659
P3659
Initial supply, for up to 3 months, for a palliative care patient with chronic severe disabling pain not responding to non-narcotic analgesics
Compliance with Authority Required procedures

 
C3660
P3660
Continuing supply for a palliative care patient with chronic severe disabling pain not responding to non-narcotic analgesics
Compliance with Authority Required procedures

[139]          Schedule 4, entry for Methylnaltrexone
substitute:
Methylnaltrexone
C3235
P3235
Initial supply, in combination with oral laxatives, for a palliative care patient with opioid-induced constipation who has failed to respond to laxatives
Compliance with Authority Required procedures

 
C3238
P3238
Continuing supply, in combination with oral laxatives, for a palliative care patient with opioid-induced constipation who has demonstrated a response to methylnaltrexone
Compliance with Authority Required procedures

[140]          Schedule 4, entry for Morphine
substitute:
Morphine
C1062
 
Chronic severe disabling pain not responding to non-narcotic analgesics
 

 
C1358
 
Severe disabling pain not responding to non-narcotic analgesics.
 

 
C1499
P1499
Chronic severe disabling pain due to cancer
Compliance with Authority Required procedures

 
C1789
P1789
Severe disabling pain due to cancer not responding to non-narcotic analgesics
 

 
C3659
P3659
Initial supply, for up to 3 months, for a palliative care patient with chronic severe disabling pain not responding to non-narcotic analgesics
Compliance with Authority Required procedures

 
C3660
P3660
Continuing supply for a palliative care patient with chronic severe disabling pain not responding to non-narcotic analgesics
Compliance with Authority Required procedures

 
C3661
P3661
Initial supply, for up to 3 months, for a palliative care patient with severe disabling pain not responding to non-narcotic analgesics
Compliance with Authority Required procedures

 
C3662
P3662
Continuing supply for a palliative care patient with severe disabling pain not responding to non-narcotic analgesics
Compliance with Authority Required procedures

[141]          Schedule 4, entry for Naproxen
substitute:
Naproxen
C1036
P1036
Bone pain due to malignant disease
 

 
C1054
P1054
Chronic arthropathies (including osteoarthritis) with an inflammatory component
 

 
C3645
P3645
Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem
Compliance with Authority Required procedures - Streamlined Authority Code 3645

 
C3646
P3646
Continuing supply for a palliative care patient where severe pain is a problem
Compliance with Authority Required procedures - Streamlined Authority Code 3646

 
C3647
P3647
Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem in patients unable to take a solid dose form of a non-steroidal anti-inflammatory agent
Compliance with Authority Required procedures - Streamlined Authority Code 3647


 
C3648
P3648
Continuing supply for a palliative care patient where severe pain is a problem in patients unable to take a solid dose form of a non-steroidal anti-inflammatory agent
Compliance with Authority Required procedures - Streamlined Authority Code 3648


[142]          Schedule 4, entry for Nevirapine
substitute:
Nevirapine
C3586
 
Where the patient is receiving treatment at/from a private hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures

 
C3587
 
Where the patient is receiving treatment at/from a private hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures

 
C3588
 
Where the patient is receiving treatment at/from a public hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3588

 
C3589
 
Where the patient is receiving treatment at/from a public hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3589

[143]          Schedule 4, entry for Nitrazepam
substitute:
Nitrazepam
 
P1123
For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal
(Authority Required)
 

 
 
P1126
For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal (Authority Required)
 

 
 
P1216
Malignant neoplasia (late stage) (Authority Required)
 

 
 
P1235
Myoclonic epilepsy (Authority Required)
 

 
 
P3653
Initial supply, for up to 4 months, for a palliative care patient where insomnia is a problem (Authority Required)
 

 
 
P3654
Continuing supply for a palliative care patient where insomnia is a problem (Authority Required)
 

[144]          Schedule 4, entry for Ondansetron
substitute:
Ondansetron
C3050
P3050
Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration
 

 
C3611
P3611
Management of nausea and vomiting associated with radiotherapy being used to treat malignancy
Compliance with Authority Required procedures - Streamlined Authority Code 3611

[145]          Schedule 4, entry for Oxazepam
substitute:
Oxazepam
 
P1123
For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal
(Authority Required)
 

 
 
P1126
For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal (Authority Required)
 

 
 
P1216
Malignant neoplasia (late stage) (Authority Required)
 

 
 
P3655
Initial supply, for up to 4 months, for a palliative care patient where anxiety is a problem (Authority Required)
 

 
 
P3656
Continuing supply for a palliative care patient where anxiety is a problem (Authority Required)
 

[146]          Schedule 4, entry for Paracetamol
substitute:
Paracetamol
C2046
P2046
Chronic arthropathies
 

 
C2094
P2094
Relief of persistent pain associated with osteoarthritis
 

 
C3649
P3649
Initial supply, for up to 4 months, for a palliative care patient for analgesia or fever where alternative therapy cannot be tolerated
Compliance with Authority Required procedures - Streamlined Authority Code 3649

 
C3650
P3650
Continuing supply for a palliative care patient for analgesia or fever where alternative therapy cannot be tolerated
Compliance with Authority Required procedures - Streamlined Authority Code 3650

[147]          Schedule 4, entry for Promethazine
substitute:
Promethazine
C3640
P3640
Initial supply, for up to 4 months, for a palliative care patient where nausea and/or vomiting is a problem
Compliance with Authority Required procedures - Streamlined Authority Code 3640

 
C3641
P3641
Continuing supply for a palliative care patient where nausea and/or vomiting is a problem
Compliance with Authority Required procedures - Streamlined Authority Code 3641

[148]          Schedule 4, entry for Raltegravir
substitute:
Raltegravir
C3586
 
Where the patient is receiving treatment at/from a private hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures

 
C3587
 
Where the patient is receiving treatment at/from a private hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures

 
C3588
 
Where the patient is receiving treatment at/from a public hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3588


 
C3589
 
Where the patient is receiving treatment at/from a public hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3589


[149]          Schedule 4, entry for Ritonavir
substitute:
Ritonavir
C3586
 
Where the patient is receiving treatment at/from a private hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures

 
C3587
 
Where the patient is receiving treatment at/from a private hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures
 
 
 

 
C3588
 
Where the patient is receiving treatment at/from a public hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3588

 
C3589
 
Where the patient is receiving treatment at/from a public hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3589

[150]          Schedule 4, entry for Saquinavir
substitute:
Saquinavir
C3586
 
Where the patient is receiving treatment at/from a private hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures

 
C3587
 
Where the patient is receiving treatment at/from a private hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures

 
C3588
 
Where the patient is receiving treatment at/from a public hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3588

 
C3589
 
Where the patient is receiving treatment at/from a public hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3589

[151]          Schedule 4, entry for Sorbitol with Sodium Citrate and Sodium Lauryl Sulfoacetate
substitute:
Sorbitol With Sodium Citrate And Sodium Lauryl Sulfoacetate
C1025
P1025
Anorectal congenital abnormalities
 

 
C1122
P1122
For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult
 

 
C1221
P1221
Megacolon
 

 
C1254
P1254
Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function
 

 
C1263
P1263
Patients receiving palliative care
 

 
C1268
P1268
Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities
 

 
C1400
P1400
Terminal malignant neoplasia
 

 
C3642
P3642
Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem
Compliance with Authority Required procedures - Streamlined Authority Code 3642

 
C3643
P3643
Continuing supply for a palliative care patient where constipation is a problem
Compliance with Authority Required procedures - Streamlined Authority Code 3643

 
[152]          Schedule 4, entry for Stavudine
substitute:
Stavudine
C3586
 
Where the patient is receiving treatment at/from a private hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures

 
C3587
 
Where the patient is receiving treatment at/from a private hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures

 
C3588
 
Where the patient is receiving treatment at/from a public hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3588

 
C3589
 
Where the patient is receiving treatment at/from a public hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3589

[153]          Schedule 4, entry for Sterculia with Frangula Bark
substitute:
Sterculia With Frangula Bark
C1025
P1025
Anorectal congenital abnormalities
 

 
C1122
P1122
For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult
 

 
C1221
P1221
Megacolon
 

 
C1254
P1254
Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function
 

 
C1263
P1263
Patients receiving palliative care
 

 
C1268
P1268
Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities
 

 
C1400
P1400
Terminal malignant neoplasia
 

 
C3642
P3642
Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem
Compliance with Authority Required procedures - Streamlined Authority Code 3642

 
C3643
P3643
Continuing supply for a palliative care patient where constipation is a problem
Compliance with Authority Required procedures - Streamlined Authority Code 3643

[154]          Schedule 4, entry for Sulindac
substitute:
Sulindac
C1036
P1036
Bone pain due to malignant disease
 

 
C1054
P1054
Chronic arthropathies (including osteoarthritis) with an inflammatory component
 

 
C3645
P3645
Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem
Compliance with Authority Required procedures - Streamlined Authority Code 3645

 
C3646
P3646
Continuing supply for a palliative care patient where severe pain is a problem
Compliance with Authority Required procedures - Streamlined Authority Code 3646

 
[155]          Schedule 4, entry for Temazepam
substitute:
Temazepam
 
P1123
For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal
(Authority Required)
 

 
 
P1126
For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal (Authority Required)
 

 
 
P1216
Malignant neoplasia (late stage) (Authority Required)
 

 
 
P3653
Initial supply, for up to 4 months, for a palliative care patient where insomnia is a problem (Authority Required)
 

 
 
P3654
Continuing supply for a palliative care patient where insomnia is a problem (Authority Required)
 

[156]          Schedule 4, entry for Tenofovir
substitute:
Tenofovir
C2931
 
Where the patient is receiving treatment at/from a private hospital
Chronic hepatitis B
Chronic hepatitis B in a patient who has failed antihepadnaviral therapy and who satisfies all of the following criteria:
(1)(a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or
(b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance;
(2) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception
Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy
Compliance with Written or Telephone Authority Required procedures

 
C3203
 
Where the patient is receiving treatment at/from a private hospital
Chronic hepatitis B
Treatment, as sole PBS-subsidised therapy, of chronic hepatitis B in a patient who is nucleoside analogue naive and satisfies all of the following criteria:
(1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);
(2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or
(b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;
(3) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception
Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy
Compliance with Written or Telephone Authority Required procedures

 
C3313
 
Where the patient is receiving treatment at/from a public hospital
Chronic hepatitis B
Chronic hepatitis B in a patient who has failed antihepadnaviral therapy and who satisfies all of the following criteria:
(1)(a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or
(b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance;
(2) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception
Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3313


 
C3417
 
Where the patient is receiving treatment at/from a public hospital
Chronic hepatitis B
Treatment, as sole PBS-subsidised therapy, of chronic hepatitis B in a patient who is nucleoside analogue naive and satisfies all of the following criteria:
(1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);
(2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or
(b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;
(3) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception
Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3417


 
C3586
 
Where the patient is receiving treatment at/from a private hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures
 

 
C3587
 
Where the patient is receiving treatment at/from a private hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures

 
C3588
 
Where the patient is receiving treatment at/from a public hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3588

 
C3589
 
Where the patient is receiving treatment at/from a public hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3589

 
[157]          Schedule 4, entry for Tenofovir with Emtricitabine
substitute:
Tenofovir with Emtricitabine
C3586
 
Where the patient is receiving treatment at/from a private hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures

 
C3587
 
Where the patient is receiving treatment at/from a private hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures

 
C3588
 
Where the patient is receiving treatment at/from a public hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3588

 
C3589
 
Where the patient is receiving treatment at/from a public hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3589

[158]          Schedule 4, entry for Tenofovir with emtricitabine and efavirenz
substitute:
Tenofovir with emtricitabine and efavirenz
C3586
 
Where the patient is receiving treatment at/from a private hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures

 
C3587
 
Where the patient is receiving treatment at/from a private hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures

 
C3588
 
Where the patient is receiving treatment at/from a public hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3588

 
C3589
 
Where the patient is receiving treatment at/from a public hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3589

 
[159]          Schedule 4, entry for Tipranavir
substitute:
Tipranavir
C3600
 
Where the patient is receiving treatment at/from a private hospital
Treatment of human immunodeficiency virus (HIV) infection, in addition to optimised background therapy in combination with other antiretroviral agents, and co-administered with 200 mg ritonavir twice daily in an antiretroviral experienced patient who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance
Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity
Compliance with Written or Telephone Authority Required procedures

 
C3601
 
Where the patient is receiving treatment at/from a public hospital
Treatment of human immunodeficiency virus (HIV) infection, in addition to optimised background therapy in combination with other antiretroviral agents, and co-administered with 200 mg ritonavir twice daily in an antiretroviral experienced patient who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance
Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity
Compliance with Written or Telephone Authority Authority Required procedures - Streamlined Authority Code 3601

 
C3602
 
Where the patient is receiving treatment at/from a private hospital
Treatment of human immunodeficiency virus (HIV) infection, in addition to optimised background therapy in combination with other antiretroviral agents, and co-administered with ritonavir in an antiretroviral experienced patient who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance.
Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity
Compliance with Written or Telephone Authority Authority Required procedures

 
C3603
 
Where the patient is receiving treatment at/from a public hospital
Treatment of human immunodeficiency virus (HIV) infection, in addition to optimised background therapy in combination with other antiretroviral agents, and co-administered with ritonavir in an antiretroviral experienced patient who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance.
Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity
Compliance with Written or Telephone Authority Authority Required procedures - Streamlined Authority Code 3603

[160]          Schedule 4, entry for Valaciclovir
substitute:
Valaciclovir
C1494
 
Where the patient is receiving treatment at/from a private hospital
Prophylaxis of cytomegalovirus infection and disease following renal transplantation in patients at risk of cytomegalovirus disease
Compliance with Authority Required procedures

 
C3419
 
Where the patient is receiving treatment at/from a public hospital
Prophylaxis of cytomegalovirus infection and disease following renal transplantation in patients at risk of cytomegalovirus disease
Compliance with Authority Required procedures - Streamlined Authority Code 3419

 
C3622
P3622
Treatment of patients with herpes zoster within 72 hours of the onset of the rash
Compliance with Authority Required procedures - Streamlined Authority Code 3622

 
C3631
P3631
Herpes zoster ophthalmicus
Compliance with Authority Required procedures - Streamlined Authority Code 3631


 
C3632
P3632
Moderate to severe initial genital herpes
Compliance with Authority Required procedures - Streamlined Authority Code 3632

 
C3633
P3633
Episodic treatment or suppressive therapy of moderate to severe recurrent genital herpes, where the diagnosis is confirmed microbiologically (by viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction) but where commencement of treatment need not await confirmation of diagnosis
Compliance with Authority Required procedures - Streamlined Authority Code 3633

 
[161]          Schedule 4, entry for Zidovudine
substitute:
Zidovudine
C3586
 
Where the patient is receiving treatment at/from a private hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures

 
C3587
 
Where the patient is receiving treatment at/from a private hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures

 
C3588
 
Where the patient is receiving treatment at/from a public hospital
Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3588

 
C3589
 
Where the patient is receiving treatment at/from a public hospital
Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3589

 
 
 
 
 
1Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 
See http://www.frli.gov.au.